B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 2 02 April 2019TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................
........................................................................................................ 4
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 4
PROTOCOL SYNOPSIS .............................................................................................................................................. 5
GLOSSARY OF ABBREVIA TIONS AND DEFINITION O F TERMS.................................................................... 13
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.2. B/F/TAF ................................................................................................................................................. 17
1.2.1. General Information ............................................................................................................. 17
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 17
1.2.3. Clinical Trials of Bictegravir and B/F/TAF ......................................................................... 18
1.3. Rationale for This Study ........................................................................................................................ 25
1.4. Rationale for Dose Selection .................................................................................................................. 26
1.5. Risk/Benefit Assessment for the Study .................................................................................................. 27
1.6. Com pliance ............................................................................................................................................ 28
2. OBJECTIVES ................................................................
..................................................................................... 29
3. STUDY DESIGN ................................................................................................................................................ 30
3.1. Endpoints ............................................................................................................................................... 30
3.2. Study Design .......................................................................................................................................... 30
3.3. Study Treatments ................................................................................................................................... 30
3.4. Duration of Treatment ............................................................................................................................ 30
4. SUBJECT POPULATION .................................................................................................................................. 31
4.1. Number of Participants and Subject Selection ....................................................................................... 31
4.2. Inclusion Criteria .................................................................................................................................... 31
4.3. Exclusion Criteria ................................................................................................................................... 32
4.4. Enrollment Criteria for Neonates ........................................................................................................... 34
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 35
5.1. Enrollment .............................................................................................................................................. 35
5.2. Description and Handling of B/F/TAF ................................................................................................... 35
5.2.1. Form ulation .......................................................................................................................... 35
5.2.2. Packaging and Labeling ....................................................................................................... 35
5.2.3. Storage and Handling ........................................................................................................... 35
5.3. Dosage and Administration ...............................................................
..................................................... 36
5.4. Prior and Concomitant Medications ....................................................................................................... 36
5.5. Accountability for B/F/TAF ................................................................................................................... 38
5.5.1. Investigational Medicinal Product Return or Disposal ......................................................... 38
6. STUDY PROCEDURES .................................................................................................................................... 39
6.1. Subject Enrollment ................................................................................................................................. 39
6.2. Pretreatment Assessments ...................................................................................................................... 39
6.2.1. Screening Visit ..................................................................................................................... 39
6.3. Subject Enrollment ................................................................................................................................. 41
6.4. Day 1 Assessments ................................................................................................................................. 41
6.5. Treatment Assessments ...............................................................
........................................................... 42
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 3 02 April 20196.5.1. Maternal treatment assessments (Weeks 4 -24 visits, Delivery Visit and 
Weeks 6 and 12 Post -partum visits) ..................................................................................... 42
6.5.2. Neonatal assessments ........................................................................................................... 43
6.5.3. Pharm acokinetic Evaluations ............................................................................................... 44
6.6. Post-treatment Assessments ................................................................................................................... 45
6.7. Early Study Drug Discontinuation Assessments .................................................................................... 45
6.7.1. 30-Day Follow -up Visit ............................................................... ......................................... 46
6.8. Criteria for Discontinuation of Study Treatment .................................................................................... 47
6.9. End of Study ..............................................................................................................................
............. 48
6.10. Post Study Care ...................................................................................................................................... 48
6.11. Virologic Failure .................................................................................................................................... 48
6.11.1. Manage ment of Virologic Rebound ..................................................................................... 48
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 51
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 51
7.1.1. Adverse Events ..................................................................................................................... 51
7.1.2. Serious Adverse Events ........................................................................................................ 52
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................
.52
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 52
7.2.2. Assessment of Severity ........................................................................................................ 53
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 53
7.4. Gilead Reporting Requirements ............................................................................................................. 55
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events ...............................................................
........................................................... 55
7.6. Toxicity Manageme nt............................................................................................................................ 56
7.6.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 56
7.6.2. Grade 3 Laboratory Abnormality or Clinical Event ............................................................. 56
7.6.3. Grade 4 Laboratory Abnormality or Clinical Event ............................................................. 57
7.7. Special Situations Reports ...................................................................................................................... 57
7.7.1. Definitions of Special Situations .......................................................................................... 57
7.7.2. Instructions for Repo rting Special Situations ....................................................................... 58
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 60
8.1. Analysis Objectives and Endpoints ........................................................................................................ 60
8.1.1. Analysis Objectives .............................................................................................................. 60
8.1.2. Primary Endpoint ................................................................................................................. 60
8.1.3. Secondary Endpoint ............................................................................................................. 61
8.1.4. Other Endpoints of Interest .................................................................................................. 61
8.2. Analysis Conventions ............................................................................................................................. 61
8.2.1. Analy sis Sets ........................................................................................................................ 61
8.3. Data Handling Conventions ................................................................................................................... 62
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 62
8.5. Efficacy Analysis ................................................................................................................................... 62
8.6. Safety Analysis ....................................................................................................................................... 63
8.6.1. Extent of Exposure ............................................................................................................... 63
8.6.2. Adverse Events ..................................................................................................................... 63
8.6.3. Laboratory Evaluations ........................................................................................................ 64
8.6.4. Other Safety Evaluations ...................................................................................................... 64
8.7. Pharm acokinetic Analysis ...............................................................
....................................................... 64
8.8. Sample Size ............................................................................................................................................ 65
9. RESPONSIBILITIES ................................................................
.......................................................................... 66
9.1. Investigator Responsibilities .................................................................................................................. 66
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 4 02 April 20199.1.1. Good Clinical Practice .......................................................................................................... 66
9.1.2. Financial Disclosure ............................................................................................................. 66
9.1.3. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... 66
9.1.4. Informed Consent ................................................................................................................. 66
9.1.5. Confidentiality ...................................................................................................................... 67
9.1.6. Study Files and Retention of Records ...............................................................
................... 67
9.1.7. Case Report Forms ............................................................................................................... 69
9.1.8. Investigational Medicinal Product Accountability and Return ............................................. 69
9.1.9. Inspections ............................................................................................................................ 69
9.1.10. Protocol Compliance ............................................................................................................ 69
9.2. Sponsor Responsibilities ........................................................................................................................ 70
9.2.1. Protocol Modifications ......................................................................................................... 70
9.2.2. Study Report and Publications ............................................................................................. 70
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 71
9.3.1. Payment Reporting ............................................................................................................... 71
9.3.2. Access to Information for Monitoring .................................................................................. 71
9.3.3. Access to Information for Auditing or Inspections .............................................................. 71
9.3.4. Study Discontinuation .......................................................................................................... 71
10. REFERENCES ................................................................................................................................................... 72
11. APPENDICES .................................................................................................................................................... 75
Appendix 1. Investigator Signature Page .................................................................................................... 76
Appendix 2. Maternal and Neonatal Study Procedures Tables ................................................................... 77
Appendix 3. Management of Clinical and Laboratory Adverse Events ...................................................... 80
Appe ndix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 81
Appendix 5. Definitions of Stage 3 Opportunist ic Illnesses in HIV (CDC Guidelines) ........................... 103
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential and 
Postpartum Contraceptive Requirements ............................................................................. 105
LIST OF IN -TEXT TABLES
Table 1-1. Pooled Virologic Outcomes of Studies 1489 and 1490 at Week 48 in 
Treatment- Naïve Patientsa...................................................................................................... 21
Table 1-2. Virologic Outcomes of Studies 1844 and 1878 at Week 48a.................................................. 23
Table 1-3. GS-US-380-1961: Virologic Outcome at Week 48 Using the US FDA -Defined 
Snapshot Algorithm and HIV -1 RNA Cutoff at 50 copie s/mL (Full Analysis Set) ............... 25
Table 5
-1. Prior and Concomitant Medications ....................................................................................... 37
Table 8-1. Statistical Comparisons for Pharmacokinetic Analyses ......................................................... 65
LIST OF IN -TEXT FIGURES
Figure 1-1. GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV -1 RNA 
(log 10copies/mL) (PP Analysis Set) ....................................................................................... 19
Figure 6-1. Virologic Rebound Schema .................................................................................................... 50
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 5 02 April 2019PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: A Phase 1b, Open -label study  to Evaluate the PK, Safety  and Efficacy  
of B/F/TAF in HIV -1 infected, Virologically  Suppressed, Pregnant 
Women in their Second and Third Trimesters
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:125589
Not applicable
Not a vailable
Study Centers 
Planned:Approximately  20centers globall y 
Objectives: The primary objective of this study is as follows:
To evaluate the stead y state pharm acokinetics (PK) of 
bictegravir (BIC) and confirm the dose of
BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg 
fixed dose combination (FDC) in the second and third trimesters of 
pregnancy
The secondary objectives of this study are as follows: 
To evaluate the stead y state PK of emtricitabine (FTC) and TAF in 
the second and third trimesters of pregnancy  
To evaluate maintenance of HIV -1 virologic suppression   in 
pregnant women receiving the B/F/TAF FDC during the second 
and/or third trimester s
The exploratory objectives of this study are as follows:
To 
assess frequency  of HIV -1 transmission from pregnant women 
taking B/F/TAF during the second and third trimesters to the 
neonate
To evaluate the safet y and tolerability  of the B/F/TAF FDC in 
HIV-1 infected virologically  suppressed pregnant women during 
the second and third trimesters through post- partum
To evaluate the safet y of B /F/TAF in neonates with in utero 
exposure to B /F/TAF
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 6 02 April 2019To explore the PK of tenofovir diphosphate (TFV -DP) in PBMCs 
in pregnancy  following administration of the B/F/TAF FDC
To explore the elimination of BIC and TAF in neonates from in 
utero exposure
To explore placental transfer of BIC and TAF
Study Design: Phase 1b, open- label, multiple dose study  in HIV-1 infected pregnant 
women in their second and/or third trimesters
Number of 
Participants
Planned:Up to 35 participants total.
At least 25 participants will be enrolled to obtain at least 20 evaluable 
pairs of PK assessments between the second trimester and post-partum
and at least 20 evaluable pairs of PK assessment between the third 
trimester and post-partum . Replacement participants may be enrolled 
if originall y enrolled participants do not complete all intensive PK 
visits as expected. 
Infants born to women particip ating in the stud y will be followed from 
birth to 4- 8 weeks of age if consent is obtained from the parents/legal 
guardian. 
Target Population: HIV-1 infected pregnant female participants who are virologically  
suppressed for ≥ 6 months prior to screening and are at least 12 w eeks 
gestation but less than 3 1
weeks gestation at the time of the Screening 
Visit .
Infants born to women participating in the stud y will be followed from 
birth to 4-8 weeks of age if consent is obtained from the parents/legal 
guardian. 
Duration of 
Treatment:Participants will be treated for up to approximately 38 weeks (from the 
second or third trimester sof pregnancy , depending on enrollment, 
through 12 weeks post -partum ). Participants who complete the study  
through Week 12 post-partum visit will be required to return to the 
clinic 30 day s after the Week 12 post-partum visit for a 30 -Day 
Follow -Up Visit.
Diagnosis and Main 
Eligibility  Criteria:HIV-1 infected women with singleton pregn ancy and meet the 
following criteria at screening : 
At least 12 weeks but not more than 31 weeks pregnant
Documented plasma HIV -1 RNA < 50 copies/mL on a stable 
regimen (or undetectable HIV
-1 RNA level according to the local 
assay  being used if the limit of detection is ≥ 50 copies/mL ) for 
≥ 6 months preceding the Screening visit
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 7 02 April 2019The last two HIV -1 RNA measurements prior to screening must be 
< 50 copies/mL ; however, unconfirmed virologic elevations of 
≥ 50 copies/mL ; (transient detectable viremia, or “bl ip”) in the past 
are acceptable.
Estimated GFR (calculated by  Cockcroft -Gault)  ≥ 90 mL /min
No documented or suspected resistance to FTC, TFV, or INSTIs 
including, but not limited to, the reverse transcriptase resistance 
mutations K65R or M184V/I
No chroni c hepatitis B virus (HBV) infection
Agree not to breastfeed for the duration of the study
Normal ultrasound with no evidence of an y fetal malformation or 
structural abnormality  affecting either fetus or placenta
Normal maternal alfa -fetoprotein level
Study  Procedures/
Frequency :MATERNAL
Following completion of Screening and Day  1 visits, eligible 
participants will be required to return for study  visits at Weeks 4, 8, 
12, 16, 20 and 24 dependent on time of enrollment (unless delivery  
has occurred b y that time point). The day  of delivery  will be 
considered as the Delivery  Visit for study  purposes. 
Following delivery , participants will be required to return for stud y 
visits for Weeks 6 an d 12 post -partum visits and a 30 -Day Follow - up 
Visit .
For all eligible participants , blood samples will be collected at Day  1 
and all subsequent visits.
For all eligible participants , urine samples will be collected at Day  1, 
Weeks 12 and 24, and Weeks 6 a nd 12 post -partum visits. 
Assessments of adverse events and concomitant medications are 
performed at each visit.
Pharmacokinetic Assessments
Study Drug Administration for Intensive Pharmacokinetic 
On the day s of intensive pharmacokinetic (iPK) sampling, study  
drug will be administered in the morning in the clinic. Following 
study  drug administration participants will fast until after 
collection of the 2 hour PK sample. Additionally , participants will 
be restricted from water consumption 1 hour before and 1 hour 
after stud y drug administration (except for the 240 mL given with 
the study  drug). 
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 8 02 April 2019If a subject is unable to fast for the iPK visit, the visit may  
proceed. Participants should be consistent if they  choose to fast or 
not fast during the iPK visits (i.e. if the participant fasts at the first 
iPK visit, then they  should fast at all other iPK visits). Diary cards 
will be provided to all participants to record the time of study  drug 
administrati on prior to the iPK visit.
PK Collection During Pregnancy:
Intensive PK visits will be completed after subject administers 
B/F/TAF for at least 3 weeks. 
For participants who enroll during the second trimester, serial 
blood samples for iPK evaluation will be collected at or between 
20 to 28 weeks of gestation, and during the third trimester, at or 
between 30 to 38 weeks of gestation.  
For participants who enroll during the third trimester, serial blood 
samples for iPK evaluation will be collected at or bet ween 30 to 
38weeks of gestation.  
PK Collection Post -partum :
Serial blood samples for iPK evaluation will be collected for all 
participants at Week 6 and Week 12 post -partum visits. 
Intensive PK Sample Collection Timepoints:
Blood samples will be collected at the following time points at the 
iPK visits: 
Pre-dose ( ≤ 5 minutes prior to dosing) 
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post -dose
A single an ytime PK sample will be collected at the Early Study 
Drug Discontinuation (ESDD) Visit, if applicable
PBMC Collection : 
For participants enrolled at sites that can process PBMC samples, a 
trough PBMC sample will be collected 24 hours following the 
in-clinic dose administered at the iPK visits.  
Sparse PK Collec tion at the Delivery Visit : A single maternal 
blood sample and an umbilical cord blood sample after cord 
clamping will be collected soon after delivery .
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 9 02 April 2019Safety  Assessments 
Complete phy sical exam: Screening, Day  1, Week 4, Week 12,
Weeks 6 and 12 post-partum , and at the ESDD Visit, if applicable. 
Symptom -driven phy sical exam: Weeks 8, 16, 20 and 2 4,and 
30-Day Follow -up Visit
Vital signs (blood pressure, heart rate, respiration rate, and bod y 
temperature): Screening, Day  1 and all subsequent 
visits
Height: Screening
Weight: Screening, Day  1 and all subsequent visits
Estimated glomerular filtration rate according to the 
Cockcroft -Gault formula : Screening, Day  1, Weeks 12 and 24,and 
Weeks 6 and12post-partum visits
Clinical laboratory  tests ( hematology , chemistry , and urinaly sis): 
Screening, Day  1, Weeks 12 and 24, Weeks 6 and12 post -partum ,
30-Day Follow -up Visit and at the E SDD visit, if applicable
Maternal alfa -fetoprotein level: Screening
Urine drug and alcohol assessments: Screening, Day 1
12-lead electrocardiogram (ECG): Screening
Hepatitis B virus, hepatitis C virus testing: Screening
HIV-1 RNA 
testing : Screening, Day  1 and all subsequent visits
CD4+ cell count: Screening, Day  1,and Week 12 post-partum
visit.
Assessments at the Delivery Visit
At the Delivery  Visit, the date of delivery  and outcome of the 
pregnancy will be recorded and a blood sample will be collected for 
HIV-1 RNA testing. Additionally , blood samples will be collected for 
PK assessments 
as described above. 
Asses sment of adverse events (AEs) and concomitant medications will 
continue throughout the study . All clinical and clinically  significant 
laboratory  toxicities will be managed per protocol requirements. 
INFANTS
Infants will be enrolled and followed from birth to 4to 8 weeks of age
if parent/legal guardian consent is provided.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 10 02 April 2019Sparse PK Collection:
Sparse PK blood samples will be collected , if possible, at the 
following time points: at or between 0 to < 2 hours, 2 to < 3 hours, 3 
to 8 hours, 18 to 28 hours, 36 to 72 hours, and 5 to 7 day s after birth.
These time points may  vary  based on birth weight, additional 
instructions will be included in the Pharmacokinetic Sample 
Collection and Processing Instructions Manual.
Neonatal Assessments 
Complete phy sical e xam: Phy sical examination at birth and once 
between 4to 8 weeks of age
Vital signs (heart rate, respiration rate, and bod y temperature): at 
birth and once between 4 to 8 weeks of age
Apgar scoring: at 5 and 10 minutes after delivery , if recorded
Anthropom etric measures: Head circumference, weight and length 
at birth and once between 4 to 8 weeks of age
Blood samples will be collected for PK assessments
HIV
-1 RNA and safety  assessments which includes CBC, LFTs 
(ALT, AST, total and direct bilirubin) may  be c ompleted using the 
sparse PK samples collected on the day  of birth, if there is 
sufficient volume. If blood volume is insufficient, results from 
testing performed per standard of care will be obtained.
HIV-1 RNA and safety  assessments may  be completed once
between 4 to 8 weeks of age or results from testing performed per 
standard of care between 4 to 8 weeks of age will be obtained.
Test Product, Dose, 
and Mode of 
Administration:FDC of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 
25mg (B/F/TAF 50/200/25 mg) administered orally , once dail y 
without regard to food
Reference Therapy, 
Dose, and Mode of 
Administration:None
Criteria for 
Evaluation:
Safety : Adverse events and clinical laboratory tests to evaluate the safety  and 
tolerability  of the treatment regimen.
Efficacy : The efficacy  endpoint is:
Maternal HIV -1 RNA < 50 copies/mL  at the time of delivery
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 11 02 April 2019Pharmacokinetics: Plasma concentrations of BIC, FTC and TAF will be determined and 
PK evaluated, as applicable. Protein binding of BIC from maternal 
intensive PK samples will be assessed at 24 hours post -dose. Protein 
binding of TAF from maternal intensive PK samples may  beassessed 
at3 hours post -dose. Plasma protein binding of BIC and TAF from 
maternal samples may  also be evaluated at an additional time point 
corresponding to T maxof the respective anal yte. Plasma concentrations 
of other metabolites may  be determined and PK explored. 
Intracellular concentrations of TFV -DP in PBMCs will be determined, 
as applicable.
The following plasma PK parameters will be calculated for BIC, FTC 
and TAF, as applicable: AUC tau, AUC last, Cmax, Ctau, Clast, Tmax, λz, 
CL/F, Vz/F, T½, and co rd blood to maternal plasma concentration ratios ,
as applicable. The PK of other anal ytes may  be explored. 
Concentrations of TFV -DP in peripheral blood mononuclear cell s
(PBMCs) will be anal yzed and C tauwill be calculated, as applicable. 
Additionally , BICand TAF T½will be calculated in infants where 
possible.
Statistical Methods: Pharmacokinetics :
Plasma concentrations and PK parameters will be listed and 
summarized using descriptive statistics by  visit for maternal and 
infant, respectively . 
An anal ysis of variance (ANOVA) using a mixed -effects model with 
visit as a fixed effect and subject as a random effect will be fitted to 
the natural logarithmic transformation of maternal PK parameters 
(AUC tau, Cmaxa
nd C tau, as applicable) for each analy te of interest. 
Two-sided 90% confidence intervals (CIs) will be calculated for the 
ratios of geometric least -squares means (GLSMs) between pregnancy  
(second or third trimester) and 12 weeks post-partum . 
The terminal half -lifeof BIC for infants, and the cord blood to 
maternal plasma concentrations ratio for BIC at delivery will be 
calculated and summarized .
Efficacy: 
The proportion of participants with plasma HIV -1 RNA 
< 50 copies/mL at the time of delivery  will be summarized using the 
missing = excluded approach for imputing missing HIV -1 RNA 
values.
Efficacy  data for infants will be listed and m aybe summarized by  visit 
if applicable.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 12 02 April 2019Safety : 
The AE data will be listed by  subject. Treatment -emergent AEs, 
serious adverse events (SAEs), and AEs leading to permanent study  
drug discontinuation will be summarized by  system organ class, and 
preferred term using the current version of the Medical Dictionary  for 
Regulatory  Activities (MedDRA).
Listings of individual subject vital signs, 12 -lead ECG par ameters, and 
laboratory  results will be provided. Laboratory  results and change 
from baseline for vital signs and selected lab tests will be summarized 
at scheduled visits. The incidence of treatment- emergent laboratory  
abnormalities will be summarized.
Safety data for infants will be listed and may  be summarized if 
applicable.
Sample Size:
With 20 evaluable 
participants, the study  has at least 74% power to 
show that the lower bound of the 90% CI of the ratio for AUC tauof 
BIC during pregnancy  relative to p ost-
partum is > 50%, assuming a 
decrease of 40% in AUC tauof BI C during pregnancy  relative to 
post-partum. I t was assumed that a standard deviation (SD) of 
BIC 
AUC tauis no more than 0.34 on a natural logarithm scale, which is 
supported by a pooled PK anal ysis from 4 previous Gilead Phase 3 
studies. With 25% overage, a total sample size of at least 
25 participants will be required.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents. 
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 13 02 April 2019GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius 
F degrees Fahrenheit
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil counts
ANOVA Analysis of Variance
ARV Antiretroviral
AST aspartate aminotransferase
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration versus time 
curve
BIC bictegravir, B , GS-9883
B/F/TAF bictegravir/emtricitabine/ tenofovir alafenamide, Biktarvy
BID twice a day 
BUN blood urea nitrogen
CBC complete blood count
CHB chronic hepatitis B
CI confidence interval
CL cr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH Cochran -Mantel -Haenszel
CNS central nervous system
COBI, /C Cobicistat
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinas e
CRF case report form(s)
CRO contract (or clinical) research organization 
CYP cytochrome P450
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DTG dolutegravir, Tivicay
ECG Electrocardiogram
eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
FAS full analysis set
EVG elvitegravir, E
E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, Genvoya
E/C/F/TDF elvitegravir/cobicistat/emtricitabine /tenofovir disoproxil fumarate, Stribild
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 14 02 April 2019FAS full analysis set
FDA (United States) Food and Drug Administration
FDC fixed dose combination
F/TAF emtricitabine/tenofovir alafenamide , Descovy
F/TDF emtricitabine/tenofovir disoproxil fumarate, Truvada
FSH follicle -stimulating horm one
FTC, F emtricitabine, Emtriva
GCP Good Clinical Practice (Guidelines)
GGT gamma glutamyl transferase
GLSM geometric least squares mean
GSI Gilead Sciences, Inc.
GS-9883 bictegravir, B , BIC
GS-9883/F/TAF GS-9883/em tricitabine/tenofovir alafenamide, B/F/TAF, Biktarvy
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HBcAb hepatitis B core antibody
HBeAb hepatitis B e- antibody
HBeAg hepatitis B e- antigen
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HDPE high-density polyethylene
HCC hepatocellular carcinoma
hERG human Ether -à-go-go-Related Gene
HIV human immunodeficiency virus
HIV Sx HIV Symptoms  Distress Module
HIV HIV Treatment Satisfaction Questionnaire
HIV-TSQs HIV Treatment Satisfaction Questionnaire Status
HIV-TSQc HIV Treatment Satisfaction Questionnaire Change
HLA human leukocyte antigen
IB investigator’s brochure
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IMP Investigational Medicinal Product
IND Investigational New Drug (Application)
INSTI integrase strand -transfer inhibitors
IRB institutional review board
IWRS interactive web response system
KS Kaposi’s sarcoma
LDH lactate dehydrogenase
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 15 02 April 2019LLN lower limit of the normal range
MedDRA Medical Dictionary for Regulatory Activities
mg Milligram
MH Mantel- Haenszel
min Minute
mmHg millimeters mercury
nM nanoMolar
NNRTI non-nucleoside reverse transcriptase inhibitor
NOEL no observed effect level
OL Open Label
NOAEL no observed adverse effect level
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
PEP post-exposure prophxylaxis
P-gp P-glycoprotein
PI protease inhibitor
PK Pharm acokinetic
PT preferred term 
PT prothrombin time 
PTM placebo -to-match
PVE Pharm acovigilance and Epidemiology
QD once daily 
RAL Raltegravir
RNA ribonucleic acid
SA single agent
SAE serious adverse event
SmPC Summary of Product Characteristics
SUSAR Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide 
TAM thymidine analogue mutation
TDF tenofovir disoproxil fumarate, Viread
TFV -DP tenofovir diphosphate (TFVpp)
tmax the time (observed time point) of C max
TSH thyroid stimulating hormone
UGT1A1 uridine 5'-diphospho -glucuronosyltransferase 
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
US United States
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 16 02 April 20191. INTRODUCTION
1.1. Background
Human immunodeficiency virus -1 (HIV -1) infection is a life -threatening and serious disease that 
is of major public health interest around the world. There are approximately  2.4million people in 
North America and Western and Central Europe living with HIV -1 and 37 million people 
worldwide {Joint United Nations Programme on HIV/AIDS (UNAIDS) 2016 }. The infection, if 
left untreated or suboptimally  treated, is characterized by  deterioration in immune function, 
ultimately  resulting in death. Therapeutic strategies for the treatment of HIV- 1 disease have been 
significantl y advanced by the availability  of highly  active antiretroviral therapy  (HAART); the 
introduction of HAART was associated with a dramatic decrease in acquired immune deficiency  
syndrome (AIDS) -related m
orbidity  and mortality  {Mocrof t 1998 , Palella 1998 , Sterne 2005}.
With the success of potent and well- tolerated antiretroviral therap y (ART) clinical attention has 
become more focused on the optimization of tolerability , long -term safet y, and adherence of 
potent ART regimens {Costagliola 2014 }.
For ART
-naive HIV -infected patients, current treatment guidelines recommend that initial 
therap y for most people consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI ) and 
an integrase strand -transfer inhibitor (INSTI) {Panel on Antiretroviral Guidelines for Adults and 
Adolescents 2018
}. 
Bictegravir (BIC) (previously  referred to as GS -9883) is a potent inhibitor of HIV -1 integrase.  
Antiviral testing has shown that BIC is active against a broad panel of HIV -1 viral lab strains and 
clinical isolates. BIC is fully  active in vitro against a panel of mutant viruses with resistance to 
NRTI s, non -nucleoside reverse transcriptase in hibitors (NNRTIs), and protease inhibitors (PIs). 
Some i ntegrase mutant viruses that are resistant to the INSTIs raltegravir (RAL) and elvitegravir 
(EVG) remain largely  sensitive to BI Cin vitro, though there is limited clinical data in this 
population .
Gilead Sciences (Gilead) has coformulated BIC with the NRTI  emtricitabine (FTC; F) and the 
NtRTI  TAF into a fixed dose combination (FDC) tablet that is suitable for once dail y use. This 
bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC provides a potent, convenient, 
tolerable, and practical regimen for the long term treatment of patients with HIV infection. 
B/F/TAF (Biktarv y®) was approved for the treatment of adults with HIV- 1 infection by  the FDA 
and is recommended in DHHS (Department of Health and Human Services) treatment 
guidelines.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 17 02 April 2019Virologically  suppressed, HIV -infected patients may  switch from their current regimen because 
of safet y or tolerability concerns or for regimen simplification. All patient populations may  
benefit from once -daily  FDC regimens as these have been shown to provide increased adherence 
and improved clinical and virologic outcomes {Aldir 2014, S terrantino 2012 }. Virologically  
suppressive ART has also contributed to a decline in HIV incide
nce in communities with high 
rates of virologic suppression, by  reducing the transmissibility  of infected individuals on 
treatment {Grabowski 2017, Kurth 2011}.
All pregnant women living with HIV infection should receive effective antiretroviral therap y 
with at least three drugs for their own health and for the prevention of perinatal transmission of 
HIV.Treatment options for pregnant women may  be limited due to risk of toxicity  
(e.g., didanosine, stavudine, full -dose ritonavir) or risk of low drug exposure and risk of 
virologic failure (e.g., elvitegravir/cobicistat) or risk of teratogenicity .  Although highl y effective 
and well tolerated treatment options are available for the treatment of HIV in fection in adults, PK 
and safet y data to inform the use of newer ARVs in pregnant women remains limited {Panel on 
Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission 
2018}.
1.2. B/F/TAF
1.2.1. General Information
Bictegravir, a potent inhibitor of HIV -1 integrase ,is now approved for the treatment of HIV 
infection as a component of FDC of B/F/TAF . 
For further information on bictegavir , refer to the 
investigator’s brochure.
1.2.2. Preclinical Pharmacology and Toxicology
A core battery  of safet y pharmacology studies have been conducted with bictegravir. These 
include assessments of cytotoxicity , off-target receptor and ion -channel binding, effects on 
human Ether -à-go-go-Related Gene (hERG) potassium current and papillary  muscle action 
potential, and in vivo studies in rats and dogs that evaluated effects of bictegravir on all major 
organ s ystems. Please refer to the investigator ’sbrochure for details.  
1.2.2.1. Pharmacology
Bictegravir is absorbed following oral administration with peak plasma concentrations occurring 
at 2
-4 hours after administration. The multiple dose pharmacokinetics of BIC are dose 
proportional over the dose range of 25 to 100 mg .Relative to fa sting conditions, administration 
with either a moderate fat (~600 kcal, 27% fat) or high fat meal (~800 kcal, 50% fat) resulted in 
an increase in BI C AUC (24%). This modest change is not considered clinically  meaningful and 
BIC can be administered with or without food.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 18 02 April 2019Bictegravir is mainly  metabolized by  uridine 5' -diphospho -glucuronos yltransferase (UGT1A1) 
and CYP3A. Bictegravir does not inhibit major human CYP isoforms or UGT1A1 at 
concentrations up to 25 M. Consequently , bictegravir is unlikely  to be a clinically  relevant 
inhibitor of these enzy mes, and is not expected to inhibit the metabolic clearance of drugs 
metabolized by  these enzy mes. Bictegravir onl y modestly  inhibits renal transporter OCT2 
(IC50= 0.42 M). As a result, bictegravir is not expec ted to significantl y interfere with the key 
transporter responsible for creatinine tubular elimination at the clinically  projected C max. 
Additionally , the risk that bictegravir will affect the OCT2 -mediated excretion of 
co-administered drugs is considered to be low.
BIC is primaril y eliminated by hepatic metabolism. Renal excretion of intact BI C is a minor 
pathway  (~1% of dose). The plasma BI C half -life was 17.3 hours.
1.2.2.2. Toxicology
The nonclinical safety profile of BI C has been well characterized in genetic t oxicology , safet y 
pharmacology  (central nervous sy stem [CNS], cardiovascular [CV], respiratory ), 
carcinogenicity , repeat -dose toxicity , and developmental toxicity  studies. Bictegravir is not 
genotoxic and did not have adverse effects on the CNS, CV, or res piratory  systems. Bictegravir 
demonstrated no carcinogenic potential in 6- month transgenic mouse or 2 -year rat 
carcinogenicity studies at exposures 15 -or 31 -fold higher, respectivel y, than the estimated 
clinical exposure of BIC when administered as B/F/TA F (50/200/25 mg), hereafter referred to as 
exposure margins. The no -observed -adverse-effects levels (NOAELs) in chronic 26- week rat and 
39-week monkey  toxicity  studies were at exposure margins of 18 -/46- fold (males/females) and 
7.0-fold, respectivel y. Admi nistration of BI C to cy nomolgus monkey s at a high dose of 
1000 mg/kg/day  for 39 weeks resulted in microscopic liver changes that persisted through the 
recovery  phase; observed increased alanine aminotransferase (ALT) activities at 1000 mg/kg/day  
exhibited reversibility . In offspring from rat and rabbit dams treated with BIC during pregnancy , 
there were no toxicologically  significant effects on developmental endpoints, and studies in 
animals administered BIC have shown no evidence of teratogenicit y or an eff ect on reproductive 
function.
1.2.3. Clinical Trials of Bictegravir and B/F/TAF
Please refer to the B/F/TAF i
nvestigator’ s brochure for a list of clinical studies of BIC and 
B/F/TAF as well as further information about these studies.
1.2.3.1. Phase 1 Safety and Pharmacoki netics
Study GS-US-141- 1218 was a four part, first -in-human study .  Parts A and B were randomized, 
double -blind, placebo -
controlled, single and multiple ascending dose studies of BIC in healthy  
male and female participants which helped establish the PK of BIC and evaluated the drug -drug 
interaction potential with F/TAF FDC. Please see the investigator ’sbrochure for additional 
details.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 20 02 April 20191.2.3.3. Summary  of Phase 2 Study  (GS-US-141-1475)
Study  GS
-US-141- 1475 is an ongoing Phase 2, randomized, double -blind, multicenter, 
active -controlled study  to assess the safety  and efficacy  of a regimen containing B IC+FTC/TAF 
versus dolutegravir (D TG)+F TC/TAF in HIV -
infected, ART- naive adult participants.
Eligible participants were randomized in a 2:1 ratio to receive BIC 75 mg + F TC/TAF 
(200/25 mg) + placebo -to-match DTG 50 mg once daily  or DTG 50 mg + F TC/TAF (200/25 mg) 
+ placebo -to-match BIC 75mg once dail y.
The primary  efficacy  endpoint was the proportion of participants with HIV -1 RNA 
50copies/mL  at Week 24 as determined b y the United States (US) Food and Drug 
Administration (FDA) -defined snapshot algorithm. The percentages of participants with HIV -1 
RNA < 50 copies/mL at Week 24 was high in both groups, as follows: BIC+F TC/TAF 96.9%; 
DTG+F TC/TAF 93.9%; difference in percentages: 2.9%, 95% CI : −8.5% to 14.2%. Because the 
lower bound of the 95% CI  for the difference in response rate 
(BIC+FTC/TAF -DTG+F TC/TAF) was greater than the prespecified −12% margin, 
BIC+FTC/TAF was determined to be noninferior to DTG+F TC/TAF.
HIV-1 RNA levels decreased rapidl y in the first 4weeks following initiation of study  drug in 
both treatment groups. No resistanc e to an y INSTIs, NRTI s, NNRTIs, or PIs was detected 
through Week 48 in the B IC+FTC/TAF group. Both B IC+FTC/TAF and DTG+F TC/TAF were 
generall y well tolerated through 48 weeks of treatment with similar proportions of adverse 
events reported in each treatment group. Participants in both groups were switched to open -label 
B/F/TAF after all participants completed 48 weeks of blinded treatment. 
1.2.3.4. Summary  of Phase 3 Studies
Treatment -Naïve Patients
In Stud y 1489, patients were randomized in a 1:1 ratio to receive e ither fixed -dose combination 
B/F/TAF (50/200/25 mg) (N = 314) or ABC/DTG/3TC (600/50/300 mg) (N = 315) once daily. 
In Stud y 1490, patients were randomized in a 1:1 ratio to receive either fixed -dose combination 
B/F/TAF (50/200/25 mg) (N = 320) or DTG + FTC /TAF (50+200/25 mg) (N = 325) once dail y.
In Studies 1489 and 1490, the mean age was 35 years (range 18-77), 89% were male, 58% were 
White, 33% were Black, and 3% were Asian. 24% percent of patients identified as 
Hispanic/Latino. The mean baseline plasma H IV-1 RNA was 4.4 log 10copies/mL  
(range 1.3-6.6). The mean baseline CD4+ cell count was 460 cells/mm3(range 0 -1636) and 
11% had CD4+ cell counts less than 200 cells/mm3. 18% of patients had baseline viral loads 
greater than 100,000 copies/mL . In both stud ies, patients were stratified by  baseline HIV -1 RNA 
(less than or equal to 100,000 copies/mL , greater than 100,000 copies/mL to less than or equal to 
400,000 copies/mL , or greater than 400,000 copies/mL ), by CD4 count (less than 50 cells/μL , 
50-199 cells/μ L, or greater than or equal to 200 cells/μL ), and by  region (US or ex -US).
Treatment outcomes of Studies 1489 and 1490 through Week 48 are
 presented in Table 1-1.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 21 02 April 2019Table 1-1. Pooled Virologic Outcomes of Studies 1489 and 1490 at Week 48 in 
Treatment -Naïve Patientsa
B/F/TAF FDC 
(N = 634)bABC/DTG/3TC
(N = 315)cDTG + 
FTC/TAF
(N = 325)d
HIV-1RNA < 50 copies/mL 91% 93% 93%
Treatment Difference (95% CI) 
B/F/TAF FDC vs. Comparator--2.1%
(-5.9% to 1.6%)-1.9%
(-5.6% to 1.8%)
HIV-1 RNA ≥50 copies/mLe3% 3% 1%
No Virologic Data at Week 48 Window 6% 4% 6%
Discontinued Study Drug Due to AE or Deathf<1% 1% 1%
Discontinued Study Drug Due to Other Reasons and 
Last Available HIV -1 RNA < 50 copies/mLg 4% 3% 4%
Missing Data During Window but on Study Drug 2% <1% 1%
a. Week 48 window was between Day 295 and 378 (inclusive).
b. Pooled from Study 1489 (N = 314) and Study 1490 (N = 320).
c. Study 1489
d. Study 1490
e. Includes patients who had ≥ 50 copies/mL in the Week 48 window; patients who discontinued early due to lack or loss of 
efficacy; patients who discontinued for rea sons other than an adverse event (AE), death or lack or loss of efficacy and at the 
time of discontinuation had a viral value of ≥ 50 copies/mL.
f. Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if t his 
resulted in no virologic data on treatment during the specified window.
g. Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent, 
loss to follow -up, etc.
B/F/TAF FDC was noninferior in a chieving HIV -1 RNA < 50 copies/mL at Week 48 when 
compared to ABC/DTG/3TC and DTG+FTC/TAF, respectivel y. Treatment outcomes were 
similar across subgroups by  age, sex, race, baseline viral load, and baseline CD4+ cell count.
In Studies 1489 and 1490, the mean increase from baseline in CD4+ count at Week 48 was 207, 
229, and 201 cells /mm3 in the pooled B/F/TAF FDC, ABC/DTG/3TC, and DTG+FTC/TAF 
groups, respectively .
Bone Mineral Density:
In Stud y 1489, bone mineral densit y (BMD) change from baseline to Week 48 was assessed b y 
dual-energy  X-ray absorptiometry  (DXA). In patients who had both baseline and Week 48 hip 
and lumbar spine BMD measurements (N = 257 and 267 in the B/F/TAF FDC group and 
N = 270 and 274 in the ABC/DTG/3TC group, for hip and lumbar spine, respectivel y), mean 
percentage changes in BMD were similar in the B/F/TAF FDC group compared to the 
ABC/DTG/3TC group for hip (−0.8% vs. −1.0%) and lumbar spine (−0.8% vs.−0.6%).
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 22 02 April 2019Virologically Suppressed Patients
In Stud y 1844, the efficacy and safet y of sw itching from a regimen of DTG + ABC/3TC or 
ABC/DTG/3TC to B/F/TAF FDC were evaluated in a randomized, double -blind study  of 
virologicall y-suppressed (HIV -1 RNA < 50 copies/mL ) HIV -1 infected adults (N = 563). 
Patients must have been stably  suppressed (HIV -1 RNA < 50 copies/mL) on their baseline 
regimen for at least 3 months prior to study  entry . Patients were randomized in a 1:1 ratio to 
either switch to B/F/TAF FDC at baseline (N = 282), or stay  on their baseline antiretroviral 
regimen (N = 281). Patients had a mean age of 45 years (range 20 -71), 89% were male, 
73% were White, and 22% were Black. 17% of patients identified as Hispanic/L atino. The mean 
baseline CD4+ cell count was 723 cells/mm3(range 124- 2444).
In Stud y 1878, the efficacy and safet y of swit ching from either ABC/3TC or FTC/TDF 
(200/300 mg) plus ATV or DRV (boosted by either COBI or RTV) to B/F/TAF FDC were 
evaluated in a randomized, open -label stud y of virologicall y-suppressed HIV -1 infected adults 
(N = 577). Patients must have been stably  suppressed on their baseline regimen for at least 
6months and I NSTI naïve prior to study  entry . Patients were randomized in a 1:1 ratio to either 
switch to B/F/TAF FDC (N = 290), or stay  on their baseline antiretroviral regimen (N = 287). 
Patients had a mea n age of 46 y ears (range 20- 79), 83% were male, 66% were White, and 
26% were Black. 19% of patients identified as Hispanic/Latino. The mean baseline CD4+ cell 
count was 663 cells/mm3(range 62 -2582). Patients were stratified by  prior treatment regimen. At 
screening, 15% of patients were receiving ABC/3TC plus ATV or DRV (boosted by  either COBI 
or RTV) and 85% of patients were receiving FTC/TDF plus ATV or DRV (boosted by  either 
COBI or RTV).
Treatment outcomes of Studies 1844 and 1878 through Week 48 are pr esented in Table 1-2.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 23 02 April 2019Table 1-2. Virologic Outcomes of Studies 1844 and 1878 at Week 48a
Study 1844 Study 1878
B/F/TAF 
FDC 
(N = 282)ABC/DTG/3TC
(N = 281)B/F/TAF 
FDC
(N = 
290)Baseline ATV-
or DRV -based 
regim en
(N = 287)
HIV-1RNA < 50 copies/mL 94% 95% 92% 89%
Treatment Difference (95% CI) -1.4% ( -5.5% to 2.6%) 3.2% ( -1.6% to 8.2%)
HIV-1 RNA ≥ 50 copies/mLb1% <1% 2% 2%
Treatment Difference (95% CI) 0.7% ( -1.0% to 2.8%) 0.0% ( -2.5% to 2.5%)
No Virologic Data at Week 48 Window 5% 5% 6% 9%
Discontinued Study Drug Due to AE or Death 
and Last Available HIV- 1 RNA < 50copies/mL2% 1% 1% 1%
Discontinued Study Drug Due to Other Reasons 
and Last Available HIV- 1 RNA <50 copies/mLc 2% 3% 3% 7%
Missing Data During Window but on Study Drug 2% 1% 2% 2%
a. Week 48 window was between Day 295 and 378 (inclusive).
b. Includes patients who had ≥ 50 copies/mL in the Week 48 window; patients who discontinued early due to lack or loss of 
efficacy; patients who discontinued for reasons other than lack or loss of efficacy and at the time of discontinuation had a 
viral value of ≥ 50 copies/mL.
c. Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent 
loss to follow -up, etc.
In Stud y 1844, at Week 48, switching to B/F/TAF FDC was noninferior to remaining on 
ABC/DTG/3TC. The percentages of patients with HIV-1 RNA ≥ 50 copies/mL  and who 
maintained HIV -1 RNA < 50 copies/mL were similar between the B/F/TAF FDC and 
ABC/DTG/3TC groups. The mean change from baseline in CD4+ count at Week 48 was 
−31cells/mm3in patients who switched to B/F/TAF FDC and 4 cells /mm3in patients who stayed 
on ABC/DTG/3TC.
In Stud y 1878, at Week 48, switching to B/F/ es of patients with HIV- 1 RNA ≥ 50 copies/mL  
and who maintained HIV -1 RNA < 50 copies/m TAF FDC was noninferior to remaining on an 
ATV -or DRV -based regimen. The percentag L were similar between the B/F/TAF FDC and 
ATV -or DRV -based regimen groups. The mean change from baseline in CD4+ count at 
Week 48 was 25 cells /mm3in patients who switched to B/F/TAF FDC and 0 cells /mm3in 
patients who stayed on their baseline r egimen.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 24 02 April 2019Bone Mineral Density:
In Stud y 1844, BMD change from baseline to Week 48 was assessed b y DXA. In patients who 
had both baseline and Week 48 hip and lumbar spine BMD measurements (N = 229 and 233 in 
the B/F/TAF FDC group and N = 242 and 244 in the A BC/DTG/3TC group, for hip and lumbar 
spine, respectivel y), mean percentage increases in BMD were similar in the B/F/TAF FDC group 
compared to the ABC/DTG/3TC group for hip (0.2% vs. 0.3%) and lumbar spine 
(0.7% vs.0.4%).
Virologically Suppressed Female Pat ients
In stud y 1961, the efficacy  and safet y of switching to B/F/TAF from either a protease inhibitor or 
boosted elvitegravir -containing regimen (E/C/F/TAF or E/C/F/TDF) was evaluated in HIV-1 
infected, virologically  suppressed women (N=470). Participants were randomized (1:1) to switch 
to B/F/TAF (234) or stay on baseline regimen (SBR, n=236 [E/C/F/TAF n=125; E/C/F/TDF 
n=98; ATV+RTV+FTC/TDF n=13]). Participant median age was 39 years 37% black, 28.3% 
white, 21.7% Asian and CD4 count was 686 cells/μ l. In Study 1961 at Week 48, switching to 
B/F/TAF FDC was noninferior to SBR. The percentages of patients with HIV -1 RNA 
≥ 50 copies/mL  and who maintained HIV -1 RNA < 50 copies/mL were similar between the 
B/F/TAF FDC and SBR groups. The median change from baselin e in CD4+ count at Week 48 
was +32 cells/mm3 in patients who switched to B/F/TAF FDC and +23 cells/mm 3in patients in 
the SBR group.
Treatment outcomes of Stud y 1961 through Week 48 are presented in Table 1-3.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 25 02 April 2019Table 1-3. GS-US- 380-1961: Virologic Outcome at Week 48 Using the US 
FDA -Defined Snapshot Algorithm and HIV- 1 RNA Cutoff at 
50copies/mL (Full Analysis Set)
B/F/TAF vs SBR
B/F/TAF
(N=234)SBR
(N=236) p-valueDifference in 
Percentages
(95.001% CI)
HIV-1 RNA < 50 copies/mL 224 
(95.7%)225 
(95.3%)1.00 0.4% ( -3.7% to 4.5%)
HIV-1 RNA >= 50 copies/mL 4 (1.7%) 4 (1.7%) 1.00 0.0% ( -2.9% to 2.9%)
HIV-1 RNA >= 50 copies/mL in Week 48 Window 4 (1.7%) 4 (1.7%)
Discontinued Study Drug Due to Lack of Efficacy 0 0
Discontinued Study Drug Due to AE/Death and Last 
Available HIV -1 RNA >= 50 copies/mL0 0
Discontinued Study Drug Due to Other Reasonsa
and Last Available HIV- 1 RNA >= 50 copies/mL0 0
No Virologic Data in Week 48 Window 6 (2.6%) 7 (3.0%)
Discontinued Study Drug Due to AE/Death and Last
Available HIV -1 RNA < 50 copies/mL0 1 (0.4%)
Discontinued Study Drug Due to Other Reasonsa
and Last Available HIV- 1 RNA < 50 copies/mL3 (1.3%) 4 (1.7%)
Missing Data During Window but on Study Drug 3 (1.3%) 2 (0.8%)
The Week 48 window is between Days 295 and 378 (inclusive).
a Other reasons include participants who discontinued study drug due to investigator's discretion, subject decision, lost to 
follow -up, noncompliance with study drug, protocol violation, pregnancy, and study terminated by sponsor.
P-values for the superiority test comparing the percentages b etween treatment groups were from the Fisher exact test.
The difference in percentages between treatment groups and their 95.001% CIs were calculated based on an unconditional exact 
method using 2 inverted 1 -sided tests.
1.3. Rationale for This Study
All pregna nt women living with HIV infection should receive effective antiretroviral therap y 
with at least three drugs for their own health and for the prevention of perinatal transmission of 
HIV.  Treatment options for pregnant women may be limited due to risk of t oxicity  
(e.g., didanosine, stavudine, full -dose ritonavir) or risk of low drug exposure and risk of 
virologic failure (e.g., elvitegravir/cobicistat) or risk of teratogenicity .  Although highl y effective 
and well tolerated treatment options are available f or the treatment of HIV infection in adults, PK 
and safet y data to inform the use of newer ARVs in pregnant women remain limited {Panel on 
Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission 
2018 }.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 26 02 April 2019The PK of man y drugs , including ARVs, has been shown to be altered during pregnancy  
{Prezista USPI , Rey ataz USPI , Edurant USPI , Tivicay  USPI }{Gilbe rt 2015 }.These changes in 
drug exposures have been attri buted to the phy siologic changes that occur during pregnancy , 
which include changes in plasma volume, protein binding, glomerular filtration rate and altered 
activity  of drug metabolizing enzy mes and transporters {Costantine 2014 , Isoherranen 2013 , 
Loebs tein 1997 }.
Bictegravir is an INSTI that is currentl y approved in a FDC of B/F/TAF for use once dail y for 
the treatment of human immunodeficiency  virus ty pe1 (HIV -1) infection in adults {Biktarv y 
USPI }.Bictegravir is metabolized by  uridine diphosphate (UDP) -glucuronosy l transferase 1A1 
(UGT1A1) and CYP3A4. I ncreased activities of CYP3A and UGT1A1 have been reported 
during pregnancy {Hebert 2008 , Jeong 2009} and decreased exposures of other ARVs that are 
substrates of these enzymes (i.e, dolutegravir and raltegravir)
 have been observed (Mulligan 
2018, Watts 2014). As such, there may  be a possibility  for reduced BIC exposures during 
pregnancy . No clinicall y relevant changes in the PK of FTC or TAF were observed in previous 
studies in HI V
-infected pregnant women {Colbers 2013, Stek 2012}. 
The primary  objective of this study  is to charact erize the pharmacokinetics (PK) of BI C and 
confirm the dose of the B/F/TAF FDC in virologically  suppressed
,HIV-1 infected pregnant 
women. Thus, this study  aims at comparing the PK of BI C, FTC and TAF in HIV -infected 
pregnant women in the second or third trimesters of pregnancy  relative to post -partum . This 
study  will also characterize placental transfer of BIC and TAF to understand drug distribution 
into the fetus and the elimination of BIC and TAF in neonates from in utero exposure. 
Pharmacokinetic and safety  data from this study  will guide dose selection of B/F/TAF in 
pregnancy .  
1.4. Rationale for Dose Selection
B/F/TAF 50/200/25 mg is the approved dose for treatment of HIV -1 infection in adults (Bikt arvy 
USPI ). 
The B/F/TAF Phase 3 studies support that virologic suppression and safet y are maintained with 
mean BI C exposures at ~50% to 200% of the mean in adults {Lutz 2018 }. Briefl y, no exposure -
safet y relationship was observed for BI C in Phase 3 , support ingthe safet y of increases in BI C 
exposures ~200% of the mean in adults
.With respect to efficacy , the results of B/F/TAF Phase 3 
exposure -efficacy  anal yses showed uniforml y high virol ogic response rates (
≥98.0%) across 
BIC exposure quartiles, with similar virologic response rates in the highest quartile and the 
lowest quartile observed. I n the Phase 3 studies, the mean protein adjusted inhibitory  quotient 
(IQ; C tau/paEC 95 [162 ng/mL ])was 16.1.
An evaluation of individual participants’ BIC IQ values as a function of whether or not the 
primary  efficacy  endpoint was met (HIV -1 RNA < 50 copies/mL  at Week 48) revealed that all 
27
participants who had IQ values at or below 50% of the Phase 3 mean IQ of 16.1 had 
HIV
-1RNA <50 copies/mL  at the Week 48 visit. Therefore, the lower boundary  of the BIC 
therapeutic window is unknown and the 50% lower limit is conservative. Importantly , the subject 
with the lowest observed BIC exposure (IQ = 4.7) w ould maintain C tauwell above paEC 95even 
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 27 02 April 2019if their exposure decreased by  50% (IQ = 2.4). As such, participants with a decrease in exposures 
of 50% of the Phase 3 mean are expected to maintain virologic suppression. 
The Phase 3 data support the safet y of increases in BIC exposures ~200% of the mean in adults. 
No exposure -safety  relationship was observed for BIC in Phase 3 and the highest observed 
individual BI C AUC tauin the Phase 3 studies was approximately  230% that of the mean Phase 3 
BIC AUC tau, indica ting that all participants with exposures around 200% of the Phase 3 mean are 
expected to maintain safety .
Changes in BIC exposure during the second and third trimesters of pregnancy  in this study  are 
expected to be within the range of those observed for other INSTIs that are substrates of CYP3A 
and UGT1A1, dolutegravir and raltegravir {Mulligan 2018 , Watts 2014} . Exposures of these 
agents decreased 20 to 50% during pregnancy  compared to post-partum . As BIC exposures 
≥ 50% of the mean in adults are expected to maintain virologic suppression and no clinicall y 
relevant changes in FTC and TAF are expecte d, B/F/TAF is anticipated to be efficacious and 
well tolerated during pregnancy .
1.5.
Risk/Benefit Assessment for the Study
Maintenance of virologic suppression is of paramount importance to protect the health of 
pregnant women and to prevent vertical transmiss ion to the infant.  In general, pregnant women 
are encouraged to continue their current ART regimen during pregnancy , assuming that it is 
effective and well -tolerated {Panel on Treatment of Pregnant Women with HIV Infection and 
Prevention of Perinatal Transmission 2018}.  However, newer, highl y effective ARVs such as 
B/F/TAF may
 provide benefits by  reducing pill burden and toxicity while maintaining highly  
efficacious therap ywithout risk of drug resistance.  Bictegravir did not show an y risk for 
embry o-fetal toxicity  in pre -clinical species . There is limited information on TAF in pregnancy , 
but TDF, a different tenofovir prodrug, is recommended in pregnancy .  Potential risks associated 
with all classes of ARVs include immune reconstitution sy ndrome, lipody strophy , and lactic 
acidosis with steatosis. The risk of class effects is considered to be low. Potential risks of 
switching 
ARVs during pregnancy  could be loss of virologic control, development of drug 
resistance to some of the medications in B/F/TAF or new side effects.  Potential benefits may  
include provision of a new ARV therap y tothis patient population that may have fewer side 
effects than alternative therapies. Other potential benefits include provisions of fixed dose 
combination therap y, and the knowledge that patient participation will contribute to the body of 
knowledge of HIV therapies. In addition, INSTIs exhibit rapid reduction of HIV- 1 viral load, 
thereb y provid ing a benefit to pregnant women with untreated HIV- 1 infection.
In summary , the risk/benefit for this study  is acceptable due to the following considerations: 
No clinically  relevant changes in the PK of FTC or TAF were observed in previous studies in 
HIV-infected pregnant women 
Changes in BIC exposure during the second and third trimesters of pregnancy  are anticipated 
to remain within the safe and efficacious ranges observed during the Phase 3 trials
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 28 02 April 2019B/F/TAF has been proven to be safe, well tolerated and effective in the treatment of 
HIV-infected patients , including in 470 women in Study GS-US-380-1961
No treatment emergent resistance developed in any patient treated with B/F/TAF during the 
Phase 2 and Phase 3 studies
The benefit -risk assessment for this s tudy is favorable at this time. 
1.6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 29 02 April 20192. OBJECTIVES
The primary objective of this study is:
To evaluate the stead y state pharmacokinetics (PK) of bictegravir (BIC) and confirm the dose 
of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination 
(FDC) in the second and third trimesters of pregnancy  
The secondary objec tives of this study are:
To evaluate the stead y state PK of emtricitabine (FTC) and TAF in the second and third 
trimesters of pregnancy  
To evaluate maintenance of HIV -1 virologic suppression  in pregnant women receiving the 
B/F/TAF FDC during the second a nd/or third trimester s
The exploratory objectives of this study are as follows:
To assess frequency  of HIV -1 transmission from pregnant women taking B/F/TAF during the 
second and third trimesters to the neonate
To evaluate the safet y and tolerability  of the B/F/TAF FDC in HIV- 1 infected virologically  
suppressed pregnant women during the second and third trimester sthrough post -partum
To evaluate the safet y of B /F/TAF in neonates with in uter oexposure to B /F/TAF
To explore the PK of tenofovir diphosphate ( TFV -DP) in PBMCs in pregnancy  following 
administration of the B/F/TAF FDC
To explore the elimination of BIC and TAF in neonates from in utero exposure
To explore placental transfer of BIC and TAF
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 30 02 April 20193. STUDY  DESIGN
3.1. Endpoints
The primary  endpoint of this study  is:
T
he PK parameter AUC tauof BIC during the second and/or third trimesters through 
post-partum
The secondary  endpoints of this study  are:
The PK parameter AUC taufor FTC and TAF, and PK parameters AUC last, Cmax, Ctau, Clast,
Tmax, T1/2, CL/F, V z/F,and λzfor BI C, FTC , and TAF, as applicable
The proportion of participants with plasma HIV -1 RNA < 50 copies/mL at the time of 
delivery  by missing = excluded approach.
3.2. Study Design
This protocol describes an open- label, multicenter, multiple -dose study  to evalua te the PK, 
efficacy , safet y and tolerability of B/F/TAF in virologicall y suppressed, HIV- 1 infected pregnant 
women in their second and third trimester s. 
3.3. Study Treatments
Participants who provide written consent and meet all eligibility  criteria will receive FDC of 
bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF 50/200/25 mg) 
administered orall y, once daily  without regard to food .
3.4. Duration of Treatment
Parti cipants will be treated for up to approximately 38 weeks. Following completion of a 30- day 
screening period and a Day  1 visit , eligible participants will be required to return for stud y visits 
at Weeks 4, 8, 12, 16, 20 and 24 dependent on time of enrollmen t (unless delivery  has occurred 
by that time point). The day
 of delivery  will be considered as the Delivery  Visit for study  
purposes.
The screening period also may  be extended under special circumstances with the explicit 
approval of Gilead Sciences.
Following delivery , participants will be required to return for stud y visits for Weeks 6 and 12 
post-partum visits. Participants who complete the study  through the Week 12 post -partum visit 
will be required to return to the clinic 30 day s after completion of the study drug dosing for a 30
-
Day Follow -Up Visit. 
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 31 02 April 20194. SUBJECT POPULA TION
4.1. Number of Participants and Subject Selection
Up to 35 participants who meet all eligibility  criteria will be enrolled .
At least 25 participants will be enrolled to obtain at least 20 evaluable pairs of PK assessments 
between the second trimesters and post-partum and at least 20 evaluable pairs of PK assessment 
between the third trimesters and post-partum . Replac ement participants may be enrolled if 
participants do not complete all intensive PK visits as expected.
Infants born to women participating in the study  will be followed from birth to 4 -8 weeks of age 
if consent is obtained from the parents/legal guardian
.
4.2. Inclusion Criteria
Participants must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)The ability  to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study proc edures
2)Female participants of age 18to < 40 yearswith singleton pregnancy , at least 12 weeks but 
not more than 31 weeks pregnant at the time of screening
3) A gree not to breastfeed for the duration of the study
4)Currently  on a stable antiretroviral regimen for ≥ 6 months preceding the screening visit
5)Documented plasma HIV -1 RNA levels of < 50 copies/mL for ≥ 6 months preceding the 
screening visit and have HIV- 1 RNA < 50 copies/mL  at the Screening Visit
a)In the preceding 6 months prior to screening, one episo de of “blip” (HIV -1 RNA 
≥ 50 copies/mL  and < 400 copies/mL) is acceptable, only  if HIV -1 RNA is 
< 50 copies/mL immedia tely before and after the blip
b) To determine virologic suppression in the preceding 6 months prior to screening, the 
lower limit of quantif ication (LLOQ) b y the local HIV -1 RNA assay  may  be used, onl y if 
its LLOQ is greater than 50 copies/mL  (e.g. LLOQ of 75 copies/mL)
6) Have no documented or suspected resistance to FTC, TFV, or INSTIs including, but not 
limited to, the reverse transcriptase re sistance mutations K65R or M184V/I .
a)Historic genoty pe reports will be collected if available
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 32 02 April 20197) H ave a normal ultrasound ,completed locall y prior to the Day 1 visit, with no evidence of an y 
fetal malformation or structural abnormality  affecting either fetus o r placenta
8)Normal maternal alfa -fetoprotein level at the Screening Visit
9)Estimated glomerular filtration rate (eGFR) 90mL/min according to the Cockcroft -Gault 
(C-G) formula {Cockcroft 1976 }:
(140 –age in years) (wt in kg) 0.85  CLcr (mL/min)
72(serum creatinine in mg/dL)
(140 –age in years) (wt in kg) 0.85   CLcr (mL /sec)
72(serum creatinine in umol/L) 0. 6786
10)Normal ECG (or if abnormal, determined b y the investigator not to be clinically significant)
11)Hepatic transaminases (AST and ALT) 5upper limit of normal (ULN)
12)Total bilirubin 1.5mg/dL  (26 umol/L), ornormal direct bilirubin
13)Adequate hematologic function (absolute neutrophil count ≥750/mm3(≥ 0.75 GI/L); 
platelets ≥50,000/mm3(≥ 50 GI /L); hemoglobin ≥ 9.5 g/dL ( ≥ 9 5 g/L))
14)Serum amy lase ≤ 5 × ULN (participants with serum amy lase > 5 ×ULN will remain eligible 
if serum lipase is ≤ 5 × ULN)
15)Participants of childbearing potential must agree to utilize protocol recommended highl y 
effective contraceptive methods or be non -heterosexually  active or practice sexual abstinence 
(as defined in Appendix 6) during the post -partum period of the study , and for 7days 
following the last dose of study  drug. 
4.3.
Exclusion Criteria
Participants who meet any of the followi ng exclusion criteria are not to be enrolled in this study .
1) H ave chronic hepatitis B virus (HBV) as determined by  either:
a)Positive HBV s urface antigen (HBsAg) at the Screening Visit
b) Negative HBV surface antigen, negative HBV surface antibody, positive HBV core 
antibody  and quantifiable HBV DNA (HBV DNA ≥ 20 I U/mL) at the Screening Visit
2)Have active hepatitis C virus (HCV) infection
a)Positive anti -HCV antibody  and negative HCV poly merase chain reaction (PCR) results 
are acceptable
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 33 02 April 20193)An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to 
screening (refer to Appendix 5)
4)Participants experiencing decompensated cirrho sis (e.g., ascites, encephalopathy , or variceal 
bleeding)
5)Have been treated with immunosuppressant therapies or chemotherapeutic agents within 
3months of study  screening, or expected to receive these agents or s ystemic steroids during 
the study  (e.g, cort icosteroids, immunoglobulins, and other immune -or cy tokine -based 
therapies)
6)Malignancy  within 5 y ears of screening other than cutaneous Kaposi’s sarcoma, completel y 
resected non
-melanoma skin cancer (basal cell carcinoma or non- invasive cutaneous 
squamous carcinoma), or completely  resected carcinoma in -situ of the cervix (CIN 3) or anus 
(AIN 3). A prior malignancy  treated with curative therapy  and for which there has been no 
evidence of disease for at least five years prior to screening is allowed.
7)Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
participant study compliance
8)Active, serious infections (other than HIV -1 infection) requiring antibiotic or antifungal 
therap y within 30 days prior to Day  1
9) Participation i n any  other clinical trial, including observational studies,  without prior 
approval from the sponsor is prohibited while participating in this trial
10)Any other clinical condition , including pregnancy  complications such as gestational diabetes
or prior ther apy that, in the opinion of the Investigator, would make the participant unsuitable 
for the study or unable to comply with the dosing requirements
11)Active tuberculosis infection
12)Known hy persensitivity  to B/F/TAF, their metabolites, or formulation excipient.
13)Participants receiving ongoing therap y with an y of the following medications in the table 
below, including drugs not to be used with B/F/TAF
Drug Class Agents Disallowed*
Antiarrhythmic Agent Dofetilide
Anticonvulsants phenobarbital, phenytoin, carbam azepine, oxcarbazepine
Antimycobacterials rifampin, rifapentine, rifabutin
Antiretrovirals Any antiretroviral drug that is not part of the study regimen
Herbal/Natural Supplements St. John’s Wort
* Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 34 02 April 20194.4. Enrollment Criteria for Neonates
Neonates must meet the following inclusion criteri onto be eligible for participation in this study .
1)Parent/legal guardian consent obtained for neonate participation. 
Neonates who meet anyof the following exclusion criteria are not to be enrolled in this study :
1)If the mother has discontinued study  drug > 24 hours prior to delivery
2)At birth, the neonate has a medical condition that, in the opinion of the I nvestigator  
precludes them from participating
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 35 02 April 20195. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Enrollment
Participants will be assigned a screening number at the time of consent. Day 1 visit cannot 
occur until the Investigator has confirmed the subject’s eligibility.
Once eligibility  has been confirmed , each subject will be assigned a unique subject number using 
Interactive Web Response Sy stem (I WRS). Once a subject number has been assigned to a 
participant, it will not be reassigned to an y other subject. The subject number assignment may  be 
performed up to 3 days prior to the in -clinic Day 1 visit provided that all screening procedures 
have been compl eted and participant eligibility  has been confirmed.
All eligible Participants will be provided B/F/TAF on Day  1 visit. The IWRS will assign study  
drug bottle numbers at each study  visit. 
5.2. Description and Handling of B/F/TAF
5.2.1. Formulation
The B/F/TAF (50/200/25 mg) tablets are capsule -shaped, film -coated purplish- brown, debossed 
with "GSI" on one side of the tablet and "9883" on the other side of the tablet. Each tablet core 
contains 50 mg of bictegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafen amide. In 
addition to the active ingredients, the B/F/TAF tablets contain croscarmellose sodium, 
magnesium stearate, and microcry stalline cellulose. The tablet cores are film- coated with iron 
oxide red, iron oxide black, poly ethylene gl ycol, poly vinyl alco hol, talc, and titanium dioxide.
5.2.2. Packaging and Labeling
B/F/TAF tablets are packaged in white, high density  polyethylene (HDPE) bottles. Each bottle 
contains 30 tablets, silica gel desiccant and poly ester packing material.  Each bottle is enclosed 
with a w hite, continuous thread, child -resistant poly propy lene screw cap with an 
induction- sealed and aluminum -faced liner.
Study  drug B/F/TAF to be distributed to centers in the US, Dominican Republic and Thailand 
shall be labeled to meet a pplicable requirements of the United States Food and Drug 
Administration (FDA), and/or other local regulations.
5.2.3. Storage and Handling
Study  drug ( B/F/TAF ) should be stored at controlled room temperature of 25°C (77°F); 
excursions are permitted between 15°C and 30°C (59°F and 86° F). Storage conditions are 
specified on the label. Until dispensed to the Participants, all bottles of study  drug should be 
stored in a securel y locked area, accessible onl y to authorized site personnel.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 36 02 April 2019To ensure the stabilit y and proper identification, study drug should not be stored in a container 
other than the container in which it was supplied. Keep the bottle tightly  closed to protect from 
moisture.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize dr ug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure through inhalation when handling.
5.3. Dosage and Administration  
B/F/TAF FDC tablets will be provided by  Gilead Sciences. 
FDC of B/F/TAF containing bictegravir 50 mg / emtricitabine 200 mg / tenofovir alafenamide 
25mg will be provided to all eligible Participants at Day  1. Study  drug will be administered 
orally  at approximately  the same time each day  without regard to food. 
5.4. Prior and Concomitant Medi cations
The use of medications for the treatment of HIV -1 infection
, other than B/F/TAF, is prohibited.
Medications listed in the following table and use of herbal/natural supplements are excluded or 
should be used with caution while participants are parti cipating in the stud y.  This list should be 
utilized in jurisdictions in which B/F/TAF has NOT been approved.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 37 02 April 2019Table 5-1. Prior and Concomitant Medications 
Drug Class Agents Disallowed* To Be Used With Caution
Medications or oral 
supplements containing 
polyvalent cations 
(e.g., Mg, Al, Ca, Fe): 
Calcium or iron 
supplements 
Cation -containing antacids 
or laxatives 
Buffered medicationsAntacids containing Al/Mg or Calcium:
B/F/TAF can be t aken under fasting conditions 
2hours before antacids containing Al/Mg or 
calcium.
Routine administration of B/F/TAF 
simultaneously with, or 2 hours after, antacids 
containing Al/Mg or calcium is not 
recommended.
Supplements containing Calcium or Iron:
B/F/TAF and su pplem ents containing calcium or 
iron can be taken together with food. Routine 
administration of B/F/TAF under fasting 
conditions simultaneously with, or 2 hours after, 
supplements containing calcium or iron is not 
recommended.
Antiarrhythmic Agent dofetilide
Anticonvulsantsphenobarbital, phenytoin, 
carbamazepine, oxcarbazepine
Antimycobacterials rifampin, rifapentine, rifabutin
AntiretroviralsAny antiretroviral drug that is 
not part of the study regimen
Hypoglycemic agentMetformin:
Refer to the prescribing information of 
metformin for assessing the benefit and risk of 
concomitant use of BIKTARVY and metformin.
Herbal/Natural 
SupplementsSt. John’s Wort
* Administration of any of the above medications must be discontinued at least 30days prior to the Day 1 visit and for the 
duration of the study.
In jurisdictions in which B/F/TAF has been approved, consult the local prescribing 
information for B/F/TAF dose recommendations with concomitant medications.
Should participants have a ne ed to initiate treatment with any  excluded concomitant medication, 
the Gilead Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
Investigator must notify  Gilead as soon as he/she is aware of the use of the excluded medication.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 38 02 April 20195.5. Accountability for B/F/TAF
The Investigator is responsible for ensuring adequate accountability  of all used and unused IMP. 
This includes acknowledgement of receipt of each shipment of B/F/TAF (quantity  and 
condition). All used and unused B/F/TAF bottles dispensed to Participants must be returned to 
the site.
B/F/TAF accountability  records will be provided to each study  site to:
Record the date received and quantity  of IMP bottles
Record the date, subject number and the IMP lotnumber dispensed
Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information.
5.5.1. Investigational Medicinal Product Return or Disposal
Return and disposal of B/F/TAF will be performed as outlined in Section 9.1.8.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 39 02 April 20196. STUDY  PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. Additional information is 
provided in the study  procedures manual.
The Investigator must document any  deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enroll ment 
It is the responsibility  of the I nvestigator to ensure that participants are eligible for study  prior to 
enrollment.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Participants will be screened within approximately 30 day s before Day  1 to determine eligibility  
for participation in the study . The following will be performed and documented at screening:
Obtain written informed consent
Obtain medical history including history  of HIV -1 disease -related events, and prior 
medications within 30 days of the screening visit
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
12-lead ECG performed supine
Height
Vital signs measurement (blood pressure, pul se, respiration rate, and temperature), including 
weight
Obtain blood samples for the following laboratory anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, am ylase (reflex l ipase 
testing is performed in participants with total amy lase > 1.5 × ULN), and TSH
Estimated glomerular filtration rate according to the Cockcroft -
Gault formula
Hematology  Profile: complete blood count (CBC) with differential and platelet count
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 40 02 April 2019Maternal a lfa-fetoprotein 
Plasma HIV -1 RNA 
Whole blood for HIV -1 genoty pe (if the sample is not collected at the screening visit, it 
may be collected at the Day  1 visit)
CD4+ cell count
Hepatitis B virus (HBV) blood panel: hepatitis B virus surface antigen (HBsAg ), hepatitis 
B virus surface antibody  (HBsAb) and hepatitis B virus core antibody  (HBcAb)
The following will be conducted b y the central laboratory if the following criteria are 
met:
If positive HBsAg, reflex testing for plasma HBV DNA, HBeAg (if negative, reflex 
HBeAb), and quantitative HBsAg
If positive HBcAb with negative HBsAg and negative HBsAb, reflex testing for 
plasma HBV DNA (if positive, reflex HBeAg). If HBeAg is performed and found to 
be negative, reflex HBeAb
Hepatitis C virus (HCVAb) serology . Participants who are HCVAb positive will have a 
HCV RNA test performed
Obtain urine samples for the following laboratory  assessments:
Urinaly sis
Drug and alcohol screening
Review concomitant medications
Record an y SAEs and all AEs related to protocol mandated procedures occurring after 
signing of the consent form 
Participants meeting all of the inclusion criteria and none of the exclusion criteria will return to 
the clinic within approximately  30 day s after screening fo r Day 1 Visit.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse events case report form (eCRF).  All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history  are to be captured on the medical history  eCRF.  
See Section 7Adverse Events and Toxicity  Management for additional details.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 41 02 April 20196.3. Subject Enrollment
Once eligibility  has been confirmed and prior to or during the Day  1 visit, the Investigator or
designee will enroll the subject using the Interactive Web Response System (I WRS). Once a 
subject number has been assigned to a participant, it will not be reassigned to any  other subject 
The subject number assignment may  be performed up to 3 days prior t o the in- clinic Day  1 visit, 
provided that all screening procedures have been completed and subject eligibility  has been 
confirmed.
6.4. Day 1 Assessments 
The following evaluations are to be completed at the Day 1 Visit. 
The Investigator must have 
confirmed el igibility before proceeding with the Day 1 visit. 
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight
Obtain blood samples for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin , bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, am ylase (reflex lipase 
testing is performed in participants with total amy lase > 1.5 × ULN), and TSH
Estimated glomerular filtration rate accor ding to the Cockcroft -
Gault formula
Hematology  Profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA 
CD4+ cell count
Obtain urine samples for the following laboratory  assessments:
Urinaly sis
Drug and alcohol screening
Dispense FDC of B/F/TA F
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 42 02 April 2019Participants should be instructed to take FDC of B/F/TAF without regard to food (except as 
noted in Table 5-1). The participant should be counseled regarding the importance of 
adherence and taking their study  medication at approximately  the same time each day  as 
directed b y the Investigator
Provide 
adosing diary  to all participants for iPK sample collection
6.5. Treatment Assessments
6.5.1. Maternal treatment assessments (Weeks 4-24 visits , Delivery Visit and 
Weeks 6 and 12 
Post- partum visits)
After completion of the Day 1 Visit, participants will return for Weeks 4, 8, 12, 16, 20 and 24 
visits dependent on time of enrollment and when delivery  may  occur. 
The day of delivery  will be 
considered as the Delivery  Visit for study  purposes. After the delivery  participants will return for 
Weeks 6 and 12 post-partum visits. 
Study  visits are to be completed within ± 2 day s of the protocol -specific visit date based on the 
Day 1 visit until delivery and within ± 2 day s based on the date of delivery  during the 
post-partum period of the study . 
The following assessments will be completed a t all visits unless otherwise specified.
Review of AEs and changes in concomitant medications
Complete phy sical exam: 
Weeks 4 and 12
Weeks 6 and 12 post-partum
Symptom -driven phy sical exam: Weeks 8, 16, 20 and 24
Vital signs (blood pressure, heart rate, 
respiration rate, and bod y temperature ) including 
weight
Obtain blood samples for the following laboratory  anal yses
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, am ylase (reflex lipase 
testing is performed in participants with total amy lase > 1.5 × ULN), and TSH (Weeks 12 
and 24,and Weeks 6 and 12 post -partum )
Estimated glomerular filtration rate according to the Cockcroft -
Gault formula (Weeks 12 
and 24,andWeeks 6 and12 post-partum )
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 43 02 April 2019Hematology  Profile: complete blood count (CBC) with differential and platelet count 
(Weeks 12 and 24,and Weeks 6 and12 post - pa rtum )
Plasma HIV -1 RNA
CD4+ cell count: Week 12 post-partum only
Intensive pharmacokinetic (iPK) evaluations will be completed as noted in Section 6.5.3.
Plasma storage samples for safet y, virology  or PK testing (except at Screening, Delivery  
Visit  and 30
-Day Follow -up Visit)
For participants enrolled at sites that can process PBMC samples, a trough PBMC sample 
will be collected 24 hours following th e in
-clinic dose administered at the iPK visits.  
Obtain urine samples for the following laboratory  assessments:
Urinaly sis (Weeks 12 and 24,and Weeks 6 and12 post-partum )
Urine pregnancy  test (Week 6 and 12 post -partum ): positive urine pregnancy  tests will be 
confirmed with a serum test. If the test is positive, the subject will be discontinued
Document dispensation and accountabilit y of FDC of B/F/TAF 
The following assessments will be completed at the Delivery  Visit :
Date of delivery  will be collected
Outcome of the pregnancy  will be collected
Plasma sample for HIV -1 RNA will be obtained
Additionally  Sparse PK samples will be collected per section 6.5.3
6.5.2. Neonatal assessments 
Infants will be followed from birth to 4- 8 weeks of age if enrolled. The following assessments 
will be completed at birth and once between 4 to 8 weeks of age unless otherwise specified:
Complete physical exam
Adverse Events
Vital signs ( heart rate, respiration rate, and bod y temperature)
Apgar scoring: at 5 and 10 minutes after delivery ,if recorded
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 44 02 April 2019Anthropometric measures: Head circumference, weight and length
Blood samples will be collected for PK evaluation as noted in Section 6.5.3 . 
HIV-1 RNA and safety  assessments (CBC and LFT (ALT, AST, total and direct bilirubin) 
may be completed using the sparse PK samples c ollected on the day  of birth, if there is 
sufficient volume. If blood volume is insufficient, results from testing performed per standard 
of care will be obtained.
HIV-1 RNA and safety  assessments (CBC and LFT (ALT, AST, total and direct bilirubin) 
may be completed between 4 to 8 weeks of age or results from testing performed per 
standard of care between 4 to 8 weeks of age will be obtained. 
If the neonate is HIV -1 positive, additional genot ypic assay  may  be completed if there is 
sufficient blood volume.
6.5.3. P harmacokinetic Evaluations
6.5.3.1. Intensive Pharmacokinetic Evaluations
PK collection during pregnancy :
Intensive PK (iPK) visits will be completed after subject has been taking B/F/TAF for at 
least 3 weeks after Day  1 Visit (i.e after Day  21)
For participants who enroll during the second trimester, serial blood samples for iPK 
evaluation will be collected at or between 20 to 28 
weeks of gestation, and during the 
third trimester, at or between 30 to 38 weeks of gestation.  
For participants who enroll during the t hird trimester, serial blood samples for iPK 
evaluation will be collected at or between 30 to 38 
weeks of gestation.  
PK collection post-partum :
For all participants, serial blood samples for iPK evaluati on will be collected at Week s 6 
and12 post -partum visits
Blood samples will be collected at the following time points at each iPK visit: 
Pre-dose ( ≤ 5 minutes prior to dosing), 
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post
-dose
A single an ytime PK sample will be collected a t the ESDD visit, if applicable
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 45 02 April 2019On the day s of iPK sampling, study  drug will be administered in the morning in the clinic. 
Following stud y drug administration participants will fast until after collection of the 2 -hour 
PK sample. Additionally , participants will be restr icted from water consumption 1 hour 
before and 1 hour after study  drug administration (except for the 240 mL given with the 
study  drug). 
If a subject is unable to fast for the iPK visit, the visit may  proceed, participants should be 
consistent if they  choose to fast or not fast during the iPK visits (i.e. if the subject fasts at the 
first iPK visit, then they  should fast at all other iPK visits). 
Subject dosing diary  will be provided to all participants to record the time of study  drug 
administration prio
r to the i PK visit. Completed dosing diaries will be collected f rom
participants on the day  of the iPK Visit. If a dosing diary is not returned, the site may ask the 
subject for the time of the last dose and if it was taken with or without food. 
6.5.3.2. Sparse PK Sample Collection at the Delivery  Visit :
A
single maternal blood sample and an umbilical cord blood sample after cord clamping will 
be collected soon after delivery .
6.5.3.3. Sparse PK Sample Collection for the enrolled neonates:
Blood samples will be collected at the following time points , if possible : at or between 0 to < 
2 hours, 2 to < 3 hours, 3 to 8 hours, 18 to 28 hours, 36 to 72 hours, and 5 to 7 days after 
birth. These time points may  vary  based on birth weight, additional instructions will be 
included in the Pharmacokinetic Sample Collection and Processing Instructions Manual.
6.6. Post-
treatment Assessments
6.7. Early Study Drug Discontinuation Assessments
If a subject discontinues their study  drug administration prior to the Week 1 2 post -partum visit, 
the subject will be asked to return to the clinic within 72 hours of stopping study  treatment for 
the Earl y Study Drug Discontinuation Visit. The subject will be asked to continue attending the 
scheduled stud y visits through the Week 1
2 post -partum visit. If this is not possible or acceptable 
to the subject or investigator, the subject may  be withdrawn from the study . 
At the ESDD Visit, any  evaluations showing abnormal results indicating that there is a possible 
or probable causal rela tionship with the study  treatment, will be repeated until the abnormality  is 
resolved (returns to the baseline value) or is otherwise explained. 
The following assessments will be completed at the ESDD Visit.
Review of AEs and changes in concomitant medica tions
Complete physical exam
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 46 02 April 2019Vital signs (blood pressure, heart rate, respiration rate, and bod y temperature) including 
weight
Obtain blood samples for the following laboratory  anal yses
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubi n, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, am ylase (reflex lipase 
testing is performed in participants with total amy lase > 1.5 × ULN), and TSH 
Hematology  Profile: complete blood count (CBC) with differential and platelet count 
Plasma HIV -1 RNA
Pharmacokinetic assessments as noted in Section 6.5.3
Obtain urine samples for the following laboratory  assessments:
Urinaly sis 
Urine pregnancy  test (if the ESDD visit is after the delivery  and if testing is clinically  
appropriate)
6.7.1.
30-Day Follow -up Visit
Participants who complete the study  through their Week 12 post-partum Visit will be required to 
return to the clinic 30 days after their Week 12 post-partum Visit for a 30
-Day Follow -Up Visit.
Participants who prematurely  discontinue study  treatment and refuse to cont inue in the study  
through the Week 12 post-partum Visit will be asked to return to the clinic 30 day s after the 
completion of the Earl y Study  Drugs Discontinuation Visit for the 30 -Day Follow -up Visit.
Those participants who prematurely discontinue study treatment and continue in the study 
through at least one subsequent visit after the Early Study Drug Discontinuation Visit will 
not be required to complete the 30 -Day Follow -up Visit.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 47 02 April 2019For the purpose of scheduling a 30 -Day Follow -Up Visit, a ± 6-day window may  be used. 
Thefollowing evaluations are to be completed at the 30 -Day Follow -Up Visit:
Review of AEs and changes in concomitant medications
Symptom -directed phy sical examination
Vital signs measureme nt (blood pressure, pulse, respiration rate, and temperature), including 
weight
Obtain blood samples for the following laboratory  anal yses
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein , albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, am ylase (reflex lipase 
testing is performed in participants with total amy lase > 1.5 × ULN), and TSH 
Hematology  Profile: complete blo od count (CBC) with differential and platelet count 
Plasma HIV -1 RNA
Obtain urine samples for the following laboratory  assessments:
Urinaly sis 
Urine pregnancy  test (positive urine pregnancy  tests will be confirmed with a serum test).
At the 30 -Day Follow -Up Visit, any  evaluations showing abnormal results believed to be a 
reasonable possibility
 of a causal relationship with study  treatment will be repeated weekl y (or as 
often as deemed prudent by  the Investigator) until the abnormality  is resolved, returns to baseline 
(Day  1) value, or is otherwise explained.  
6.8. Criteria for Discontinuation of Study Treatment
Study  medication may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the I nvestigator, affect assessmen ts of 
clinical status to a significant degree . Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the Investigator.
Unacceptable toxicity , or toxicity  that, in the judgment of the I nvestigator, compromises the 
ability  to continue study -specific procedures or is considered to not be in the subject’s best 
interest
Lack of efficacy
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 48 02 April 2019Subject request to discontinue for an y reason
Subject noncompliance
Discontinuation of the study at the request of Gile ad, a regulatory  agency  or an institutional 
review board or independent ethics committee (IRB/IEC)
6.9. End of Study
The end of the stud y will be the last subject’s last observation (or visit).
6.10. Post Study Care
After the subject has completed/terminated their participation in the study , long -term care for the 
participant will remain the responsibility  of their primary  treating ph ysician.
6.11. Virologic Failure
Virologic failure is defined as confirmed virologic rebound of HIV-1 RNA ≥ 50 copies/mL  at 
2consecutive visits.
6.11.1. Management of Virologic Rebound
Participants who meet the criteria listed below will be considered to have virologic rebound 
(VR):
At any  post Day  1 visit, a rebound in HIV -1 RNA ≥ 50 copies/mL
If the HIV -1 RNA is ≥ 50 and < 200copies/mL, a reflex HIV-1 RNA repeat test will be 
conducted on available plasma samples. If the repeat result is < 50 copies/mL , no further action 
is required. If the repeat result is ≥ 50 copies/mL  participants will be asked to return to the clinic 
for a scheduled or unsched
uled blood draw (2 to 3 weeks after the date of the original test that 
resulted in HIV -1 RNA VR) for confirmation of VR. 
If virologic rebound is confirmed at the scheduled or unscheduled visit and the HIV -1 RNA is 
≥ 200 copies/mL , the plasma sample from the confirmation visit will be the primary  sample used 
for HIV -1 genot ypic and phenotypic testing.  If resistance to study treatment is detected subject 
may be discontinued at Investigator’s discretion or per local treatment guidelines.
If no resistance to 
study  treatment is detected from the genoty pe or phenot ype, the participant 
may remain on study  treatment and HIV -1 RNA should be anal yzed at a new visit (within 2 to 
3 weeks after date of test with HIV- 1 RNA ≥ 50 copies/mL ). Investigators should carefully
evaluate the benefits and risks of remaining on study  treatment for each subject and document 
this assessment in the on- site medical record.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 49 02 April 20196.11.1.1. Participants with HIV -1 RNA ≥ 50 copies/mL  at Study  Drug Discontinuation
Participants with HIV -1 RNA ≥ 50 copies/m L at study  drug discontinuation or last visit will be 
considered virologic failures and will be asked to return for an unscheduled visit within 2 to 
3weeks for a retest.
Participants with HIV -1 RNA ≥ 200 copies/mL  at study  drug di scontinuation or last visit will 
also have resistance testing conducted.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 50 02 April 2019Figure 6-1. Virologic Rebound Schema
a. If the HIV -
1 RNA is between 50 and 200 copies/mL, a reflex HIV -1 RNA repeat test will be conducted on available plasma 
samples . If the repeat result is < 50 copies/mL, then no further action is required. If the repeat result is ≥ 50 copies/mL then 
proceed to the scheduled or unscheduled visit 2 –3 weeks later.
b. If the re testresult is < 50 copies/mL, then no furthe r action is required. If the re testresult is > 50 copies/mL this is protocol 
defined confirmed virologic failure and the Medical Monitor should be consulted. 
c. If virologic rebound is confirmed and the last HIV -1 RNA is ≥ 200 copies/mL, the HIV -1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed. If the genotype and phenotype assay fails, Investigator reviews stud y 
treatment continuation/discontinuation options and discuss with the Medical Monitor prior to study treatme nt 
discontinuation.   
d. If no new resistance to study treatment is detected, HIV-1 RNA will be repeated 2 –3 weeks later. Investigator reviews 
study treatment continuation/discontinuation options and discuss with the Medical Monitor prior to study treatmen t 
discontinuation. The participant will remain in the study.
e. A new ARV regimen may be configured, at the Investigator’s discretion and the participant will remain in the study.
       
 
 
       
  
 
         
          
  
 
     
    
     
   
          
      
      
    
   
 
   
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 51 02 April 20197. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse R eactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product, which does not necessarily  have a causal relationship with the 
treatment. An AE can t herefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may  also include pre -or post -treatment complications that oc cur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (eg. hospitalization for 
elective surgery , social and/or convenie nce admissions)
Overdose without clinical sequelae (see Section 7.7)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 52 02 April 20197.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event tha t, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: s uch events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is reportable under 
expedited reporting rules. Examples of medically  important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.2. Assessment of Adverse Events and Serious Adverse Events
The Investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessmen ts.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The Investigator or qualified subinvestigator is responsible for assessing the relationship to IMP 
therap y using clinical judgment and the following considerations:
No: Evidence exists that the adv erse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused b y the 
investigational medicinal product.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 53 02 April 2019It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedur es such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg., v enipun cture)
7.2.2. Assessment of Severity 
AE severit y should be recorded and graded according to the GSI Grading Scale for Severity of
Adverse Events and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with
laboratory  
abnormalities, the event should be graded on the basis of the clinical severit y in the
context of the underly ing conditions; this may  or may  not be in agreement with the grading of
the laboratory  abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted.
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For
example, a headache may be severe in intensity , but would not be classified as serious unless it
met one of the criteria for serious events.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the
clinical severit y in the context of the underlying cond itions; this may  or may  not be in agreement
with the grading of the laboratory  abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study  drug initiat ion:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be report ed on the electronic case report form ( eCRF): all SAEs and adverse events 
related to protocol -mandated procedures.
Adverse Events
Follow ing initiation of study  medication, collect all AEs, regardless of cause or relationship, 
until 30 day s after last administration of study  IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 55 02 April 2019Additional information may  be requested to ensure the timely  completion of acc urate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the participant’s eCRF and the event description section of the SAE 
form
7.4. Gilead Reporting Requirements
Depending on relevan t local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may  be required to expedite t o 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). I n accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notif y worldwide regulatory  
agencies and the relevant I EC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy .
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuatio n must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x
-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory  
abnormality
 is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
Severity  should be recorded and grad ed according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities (refer to Appendix 4). For AEs associated with 
laboratory  abnormalit ies, the event should be graded on the basis of the clinical se
verity in the 
context of the underly ing conditions; this may  or may not be in agreement with the grading of 
the laboratory abnormality .
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 56 02 April 20197.6. Toxicity Management 
All clinical and clinicall y signific ant laboratory  toxicities will be managed according to uniform 
guidelines detailed in as outlined below :
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the Gilead Grading Scale for Severit y of Adverse Events and Laboratory  Abnormalities 
(refer to Appendix 4)
Grade 3 and 4 clinicall y significant laboratory  abnormalities should be confirmed by  repeat 
testing within 3 calen dar day s of receipt of results and before study  drug discontinuation, 
unless such a delay  is not consistent with good medical practice .
Any questions regarding toxicity  management should be directed to the Gilead Medical Monitor.
7.6.1. Grades 1 and 2 Laboratory 
Abnormality or Clinical Event
Continue study  drug at the discretion of the Investigator.
7.6.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade 3 clinically  significant laboratory  abnormality  or clinical event, study  drug may  be 
continued if the event is considered to be unrelated to study  drug.
For a Grade 3 clinical event, or clinicall y significant laboratory abnormality confirmed b y 
repeat testing, that is considered to be related to study  drug, study  drug will be withheld until 
the toxicity  returns to ≤Grade 2. When restarting study  drug following resolution of the 
adverse event, the stud y drug should be restarted at full dose upon discussion with the Gilead 
Medical Monitor.
If a laboratory  abnormality  recurs to Grade 3 following rechallenge with study  drug and is 
considered related to study  drug, then study  drug will be permanentl y discontinued and the 
participant managed according to local practice. Recurrence of laboratory  abnormalities 
considered unrelated to study  drug may  not require permane nt discontinuation but requires 
discussion with the Gilead Medical Monitor.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 57 02 April 20197.6.3. Grade 4 Laboratory Abnormality or Clinical Event
For a Grade 4 clinical event or clinicall y significant Grade 4 laboratory abnormality 
confirmed b y repeat testing that is considere d related to study  drug, study  drug will be 
permanentl y discontinued and the participant managed according to local practice. The 
participant should be followed as clinicall y indicated until the laboratory abnormality returns 
to baseline or is otherwise ex plained, whichever occurs first. A clinically  significant Grade 4 
laboratory  abnormality  that is not confirmed by  repeat testing should be managed according 
to the algorithm for the new toxicity  grade.
Study  drug may  be continued without dose interruption for a clinicall y non -significant 
Grade 4 laboratory  abnormality  (eg, Grade 4 CK after strenuous exercise, or trigl yceride 
elevation that is nonfasting or that can be medically  managed) or a clinical event considered 
unrelated to stud y drug .
Treatment -emerg ent toxicities will be noted by  the investigator and brought to the attention 
of the Gilead medical monitor, who will have a discussion with the investigator and decide 
the appropriate course of action. Whether or not considered treatment -related, all participants
experiencing AEs must be monitored periodically  until sy mptoms subside, any  abnormal 
laboratory  values have resolved or returned to baseline levels or they  are considered 
irreversible, or until there is a satisfactory
 explanation for the changes observed.
Any questions regarding toxicity  management should be directed to the Gilead 
Medical Monitor.
7.7. Special Situations Reports
7.7.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose ,reports 
of adverse events associated with product complaints regardless of an associated AE , outcome of 
the pregnancy  during the study , and pregnancy  reports during the post -partum period of the 
study , an AE in an infant following exposure from breastfeed ing,and an occupational exposure 
with an AE .  
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer. 
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing inf ormation.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 59 02 April 20197.7.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead PVE within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMP and/or Gilead concomitant 
medications, but do not apply to non- Gilead concomitant medications. 
Special situations involving non -Gilead concomitant medications do not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by
 this protocol should not be 
reported as “misuse,” but may  be mo re appropriately  documented as a protocol deviation.
Refer to the eCRF completion guidelines for full instructions on the mechanism of special 
situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AE s or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 60 02 April 20198. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary objective of this study is:
To evaluate the stead y state PK of BI C and confirm the dose of B/F/TAF 50/200/25 mg FDC 
in the second and third trimesters of pregnancy
The secondary objectives of this study are:
To evaluate the stead y state PK of FTC and TAF in the second and third trimesters of 
pregnancy  
To evaluate maintenance of HIV -1 virologic suppression in pregnant women receiving the 
B/F/TAF FDC during the second and/or third trimesters
The exploratory objectives of this study are as follow s:
To assess frequency  of HIV -1 transmission from pregnant women taking B/F/TAF during the 
second and third trimesters to the neonate
To evaluate the safet y and tolerability  of the B/F/TAF FDC in HIV- 1 infected virologically  
suppressed pregnant women durin g the second and third trimester sthrough post -partum
To evaluate the safet y of B /F/TAF in neonates with in utero exposure to B /F/TAF
To explore the PK of TFV- DP in PBMCs in pregnancy  following administration of the 
B/F/TAF FDC
To explore the elimination of BIC and TAF in neonates from in utero exposure
To explore placental transfer of BIC and TAF
8.1.2. Primary Endpoint
The primary  endpoint is the PK parameter AUC tauof BIC during the second and/or 
third trimesters through post-partum .
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 61 02 April 20198.1.3. Secondary Endpoint
Secondary endpoints include:
The PK parameter AUC taufor FTC and TAF, and PK parameters AUC last, Cmax, Ctau, Clast,,
Tmax, T1/2, CL/F, V z/F and λzfor BI C, FTC and TAF, as applicable
The proportion of participants with plasma HIV -1 RNA < 50 copies/mL at the time of 
delivery  bymissing = excluded approach.
8.1.4. Other Endpoints of Interest
Other endpoints of interest 
include the PK of PBMC -associated TFV -DP, cord blood to maternal 
plasma concentration ratio for BI C and TAF, as applicable and BIC and TAF T1/2in infants, 
where possible. They  also include the incidence of AEs and laboratory  abnormality  in infants.
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. All Enrolled
The All Enrolled anal ysis set includes all participants who are enrolled into the study .This is the 
primary  anal ysis set for by -subject listings.
8.2.1.2. Safety  Anal ysis Set
The primary  anal ysis set for 
safety  analyses is defined as safety  anal ysis set, which will include 
all participants who (1) enroll into the study  and (2) have received at least 1 dose of study  drug 
(ie,B/F/TAF). All the data collected up to 30 day s after p articipants permanently  discontinue 
their study  drug will be included in the safety  summaries, unless specified otherwise.
8.2.1.3. Efficacy
The primary  anal ysis set for efficacy analyses is defined as full anal ysis set (FAS), which will 
include all participants who (1) enroll into the study  and (2) have received at least 1 dose of 
study  drug (ie, B/F/TAF).
8.2.1.4. Pharmacokinetics
Maternal: The primary  analy sis set for PK anal yses is defined as the PK analy sis set, which will 
include all participants who (1) enroll into the study , (2) have received at least 1 dose of study  
drug (ie, B/F/TAF), and (3) have at least 1 nonmissing PK concentration data for an y analyte of 
interest report ed by the PK lab.
Infant: The PK analy sis set for infant will include all infants who (1) enroll into the study , 
(2)have at least 1 nonmissing PK concentration data for any  anal yte of interest reported b y the 
PK lab.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 62 02 April 20198.3. Data Handling Conventions
HIV-1 RNA re sults of ‘No HIV -1 RNA detected’ and ‘< 20 cp/mL  HIV-1 RNA Detected’ will 
be imputed as 19 copies/mL  for anal ysis purpose. Logarithm (base 10) transformation will be 
applied to HIV -1 RNA values for efficacy  anal ysis.
Natural logarithmic transformation of p lasma concentration and PK parameters will be applied 
for PK anal ysis.
Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus 
or minus 1 significant digit, respectivel y (eg, if the result of a continuous laboratory test is < 20, 
a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missing pre -treatment laboratory  result would be 
treated as normal (ie, no toxicity  grade) for the laboratory  abnormality  summary .
All available data for participants that do not complete the study  will be included in d ata listings.
8.4.
Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables, and freq uency  and percentages for categorical variables.
Demographic summaries will include sex, race, ethnicity , and age.
Baseline data will include a summary  of body  weight, height, body  mass index, eGFR, and 
HIV-1 infection .
8.5. Efficacy Analysis
The primary  efficacy  endpoint is the proportion of participants with plasma HIV -1 RNA 
< 50 copies/mL at the time of delivery .It will be anal yzed using the missing = excluded 
approach for imputing missing HIV -1 RNA values: all missing data will be excluded in the 
computation of the percentages (ie, missing data points will be excluded from both the numerator 
and denominator in the computation). The denominator for the percentages at a v isit is the 
number of participants in the FAS with nonmissing HIV- 1 RNA value at that visit.
The 95% CI of the proportion of participants with HIV -1 RNA < 50 copies/mL  will be provided 
using the Clopper -Pearson Exact method. 
The efficacy  data for infants may be summarized if applicable .
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 63 02 April 20198.6. Safety Analysis
All safet y anal yses will be performed using the safety  anal ysis set.
All safet y data collected on or after the date that the study  drug was first dispensed up to the date 
of last dose of the study  drug plus 30 day swill be summarized for participants in the safet y 
analysis set
. Data for the pretreatment will be included in data listings for all enrolled 
participants. 
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  drug (ie, Gilead dispensed 
B/F/TAF) will be generated 
from the study  drug administration data. Exposure data will be summarized. 
Duration of exposure to study  drug will be expressed as the number of weeks between the first 
and the last dose of B/F/TAF, inclusive, regardless of temporary  interruptions in study  drug 
administration.
Dosing information for individual 
participants will be listed.
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Cla ss (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
advers e event will be defined as any  adverse event with onset date on or after the 
study  drug start 
date and no later than 30 day s after thestudy  drug stop date; or any adverse event leading to 
study  drug discontinuation.
Summaries (number and percentage of participants) of treatment -emergent adverse events (b y 
SOC, and PT) will be provided .Additional summaries will include summaries for adverse events 
by grade, Investigator’s assessment of relationship to study  drug, and effect on study  drug 
dosing.
On an on going basis, adverse events will be reviewed for events that might meet the definition of 
Stage 3 Opportunistic I llnesses in HIV are indicative of an AIDS -Defining Diagnoses. The 
Gilead medical personnel will review the possible Stage 3 events and approve the events that 
meet the definition. Those events that do meet the Stage 3 Opportunistic I llness definition of an 
AIDS-Defining Diagnosis will be listed.
A listing of Stage 3 Opportunistic I llnesses in HIV can be found in Appendix 5.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 64 02 April 20198.6.3. Laboratory Evaluations
Selected laboratory  data (using conventional units) will be summarized using onl y observed data. 
Absolute values and change sfrom baseline at all scheduled time points will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme in Appendix 4.
Incidence of treatment -
emergent laboratory  abnormalities, defined as values that increase at least 
1 toxicity  grade from baseline at an y time post baseline up to and including the date of last dose 
of study  drug plus 30 days, will be summarized. I f baseline data are missing, then any graded 
abnormality  (ie, at least a Grade 1) will be considered treatment emergent. The maximum post 
baseline toxicity  grade will be summarized by  laboratory  parameter.
Laboratory  abnormalities that occur before the first dose of study  drug or after the last dose of 
study  drug plus 30 day s will be included in a data listing .
8.6.4. Other Safety Evaluations
Vital signs will be summarized as appropriate. Safety  data for infants might be summarized if 
necessary .
8.7. Pharmacokinetic Analysis
Maternal:
Plasma concentrations of BIC, FTC, and TAF will be summarized by  nominal sampling time 
using descriptive statistics. Pharmacokinetic parameters (AUCtau, Cmax, Ctau, Tmax, and T½, 
as appropriate) will be listed and summarized for BIC, FTC, and TAF using descriptive statistics 
(eg, sample size, arithmetic mean, geometric mean, % coefficient of variation, SD, median, Q1, 
Q3, minimum, and maximum). Plasma concentrations over time will be plotted in semi 
logarithmic and linear formats as mean SD, and median (Q1, Q3) .
In addition, an ANOVA using a mixed -effects model with visit as a fixed effect and subject as a 
random effect will be fitted to the natural logarithmic transformation of PK parameters (AUC tau, 
Cmaxand C tau, as applicable) for each anal yte of interest (ie, BIC, FTC, and TAF) . Two -sided 
90% CI swill be calculated for the ratios of GLSMs between pregnancy  (second and 
third trimester s) and post-partum (6 and 12 weeks after delivery , respectively ).
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 65 02 April 2019Table 8-1. Statistical Comparisons for Pharmacokinetic Analyses
Analytes PK Param eterComparison No Effect Boundary
for Lower Bound of 
90% CI Test Reference
BICAUC tau
Cmax
CtauSecond Trimester 12 Weeks post -partum >50%
BICAUC tau
Cmax
CtauThird Trimester 12Weeks post -partum >50%
BICAUC tau
Cmax
CtauSecond Trimester 6 Weeks post -partum >50%
BICAUC tau
Cmax
CtauThird Trimester 6 Weeks post -partum >50%
Infant:
Plasma concentration of BIC will be summarized by  nominal sampling time using descriptive 
statistics. The termin al half -lifeof BIC wil l be calculated , where possible, and summarized .
The cord blood to maternal plasma concentrations ratio for BIC and TAF, as applicable, will be 
calculated, where possible, and summarized.
8.8. Sample Size
With 20 evaluable participants, the study  hasat least 74% power to show that the lower bound of 
the 90% CI 
of the ratio for AUC tauof BI C during pregnancy  relative to post-partum is > 50%, 
assuming a decrease of 40% in AUC tauof BI C during pregnancy  relative to post- partum. It was 
assumed that a standard deviation (SD) of BIC AUC tauisno more than 0.34 on a natural 
logarithm scale, which is supported by  a pooled PK anal ysis from 4 previous Gilead B/F/TAF 
Phase 3 studies. With 25% overage, a total sample size of at least 25 participants will be 
required.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 66 02 April 20199. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with I CH E6(R2) Good 
Clinical Practices and applicable laws and regulations.
9.1.2. Financial Disclosure
The investigator and subinvestigators will provide documentation of their financial interest or 
arrangements with Gilead, or proprietary  interests in the investigational drug under study . This 
documentation must be provided prior to the investigator’s (and an y subinvestigator’s) 
participation in the study
. The investigator and subinvestigator agree to notify  Gilead of any  
change in reportable interests during the study  and for 1 y ear following completion of the study . 
Study  completion is defined as the date when the last subject completes the protocol -defined 
activities.
9.1.3. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investiga tor (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submi t to and receive documented approval from 
the 
any modifications made to the protocol or an y accompan ying material to be provided to the 
subject after initial approval, with the exception of those necessary  to reduce immediate risk to 
study  participants.
9.1.4. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study
, including the infants who may  enroll, after adequate explanation of 
the aims, methods, objectives, and potential hazards of the study  and before undertaking any  
study -related procedures. The investigator must use the most current IRB-or IEC-approved 
consent form for documenting written informed consent. Each informed consent will be 
appropriatel y signed and dated b y the su bject or the subject’s legall y authorized representative 
and the person conducting the consent discussion, and also b y an impartial witness if required b y 
local requirements. The consent form will inform participants about pharmacogenomic testing 
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 67 02 April 2019and sampl e retention, and their right to receive clinically  relevant pharmacogenomic anal ysis 
results.
9.1.5. Confidentiality
The investigator must assure that participants ’ anony mity will be strictly  maintained and that 
their identities are protected from unauthorized parties. Only  an identification code and any  other 
unique identifier(s) as allowed by  local law (such as y ear of birth) will be recorded on any  form 
or biological sample submitted to the Sponsor or laboratory. Laboratory specimens must be 
labeled in such a way as to protect subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions . NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all 
participants screen ed and for all 
participants enrolled in the trial. Subject data will be processed in accordance with all applicable 
regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator ’sbrochure, th is protocol, e CRF , the IMP, and any  other study  information, remain 
the sole and exclusive property  of Gilead during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.6.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, and 
governmental approval w ith correspondence, informed consent, drug records, staff curriculum 
vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information f or each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of t he reason(s) a consented subject is not enrolled
Participation in study  (including study  number);
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 68 02 April 2019Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety
 parameters (start and end date, and including 
causality  and severity );
Conc omitant medication (including start and end date, dose if relevant; dose changes);
Date of stud y completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified b y regulatory  requir ements, by local regulations, or by an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gile ad must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for an y or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 69 02 April 20199.1.7. Case Report Forms
For each subject consented, an eCRF casebook will be completed by  an authorized study  staff 
member whose training for this function is completed in EDC. The eCRF casebook will only  
capture the data required per the protocol schedule of events and procedures. The 
Inclusion/Exclusion Criteria and Enrollment eCRFs should be completed only  after all data 
related to eligibility  have been received. Subsequent to data entry , a stud y monitor will perform 
source data verification within the EDC sy stem. System -gener ated or manual queries will be 
issued to the investigative site staff as data discrepancies are identified b y the monitor or internal 
Gilead staff, who routinely  review the data for completeness, correctness, and consistency .The 
site coordinator is respo nsible for responding to the queries in a timel y manner, within the 
system, either b y confirming the data as correct or updating the original entry , and providing the 
reason for the update (e.g. data entry  error). Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem. Prior to any  interim time points or database lock 
(as instructed b y Gilead), the investigator will use his/her log in credentials to confirm that the 
forms have been reviewed, and that the entr ies accuratel y reflect the information in the source 
documents. At the conclusion of the trial, Gilead will provide the site with a read -only archive 
copy  of the data entered by  that site. This archive must be stored in accordance with the records 
retent ion requirements outlined in Section 9.1.6.
9.1.8. Investigational Medicinal Product Accountability and Return
Where possible, IMP should be destro yed at the site. If the site has an appropriate SOP for drug 
destruction as determined by  Gilead, the site may destroy  used (empt y or partially empty) and 
unused IMP supplies in accordance with that site’s approved SOP. A cop y of the site’s approved 
SOP will be obtained for central files. If IMP is destroy ed on site, the investigator must maintain 
accurate records for all IMP destroy ed. Records must show the identification and quantity  of 
each unit destro yed, the method o f destruction, and the person who disposed of the IMP. Upon 
study  completion, copies of the IMP accountability  records must be filed at the site. Another 
copy  will be returned to Gilead. 
If the site does not have an appropriate SOP for drug destruction, u sed and unused IMP supplies 
are to be sent to the designated disposal facilit y for eventual destruction. The study monitor will 
provide instructions for return.
9.1.9. Inspections
The investigator will make available all source documents and other records for thi s trial to 
Gilead’s appointed stud y monitors, to IRBs, or to regulatory  authorit y or health authority 
inspectors.
9.1.10. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations desc
ribed in this protocol.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 70 02 April 20199.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  participants, 
may be made onl y by Gilead. The investigator must submit all protocol modifications to the IRB
in accordance with local requirements and receive documented approval before modifications 
can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) 
may beprepared and provided to the regulatory  agency . Gilead 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases. 
Investigators in this study  may  communicate , orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study
 in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least 2 years
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 days before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.5).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 day s in order to obtain patent protection if 
deemed necessary .
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 71 02 April 20199.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance a t Investigator's Meetings.  If required under the applicable statutory  
and regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, mea l, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
ECRF .
The monitor is responsible for routine review of the ECRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the ECRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Ac cess to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory auth ority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies),IRBs, and IECs. In terminating the stud y, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the participants’ interests.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 72 02 April 201910. REFERENCES
Aldir I , Horta A, Serrado M. Single -tablet regimens in HI V: does it reall y make a difference? 
Curr Med Res Opin 2014;30 (1):89-97.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wy en C, et al. The 
pharmacokinetics, safet y and efficacy  of tenofovir and emtricitabine in HIV-1-
infected pregnant women. AIDS 2013;27 (5):739 -
48.
Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 (4):294 -301.
Costantine MM. Phy siologic and pharmac okinetic changes in pregnancy . Front Pharmacol 
2014;5:65.
Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral Pharmacokinetics in 
Pregnant Women. Pharmacotherap y 2015;35 (9):838 -55.
Grabowski MK, Serwadda DM, Gray  RH, Nakigozi G, Kigozi G, Kagaa yi J, et al. HI V 
Prevention Efforts and Incidence of HIV in Uganda. N Engl J Med 2017;377 
(22):2154-66.
Hebert MF, Easterling TR, Kirby  B, Carr DB, Buchanan ML, Rutherford T, et al. Effects of 
Pregnancy  on CYP3A and P -glycoprotein Activities as Measured b yDisposition 
of Midazolam and Digoxin: A University of Washington Specialized Center of 
Research Stud y. Clin Pharmacol Ther 2008;84 (2):248 -53.
Isoherranen N, Thummel KE. Drug Metabolism and Transport During Pregnancy : How Does 
Drug Disposition Change during Pregnancy  and What Are the Mechanisms that 
Cause Such Changes? Drug Metab Dispos 2013;41 (2):256-62.
Jeong S, Ngu yen PD, Desta Z. Comprehensive in vitro analy sis of voriconazole inhibition of 
eight cy tochrome P450 (CYP) enzy mes: major effect on CYPs 2B6, 2C9, 2C19, 
and 3A. Antimicrob Agents Chemother 2009;53 (2):541 -51.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Aids Update 2016. Available 
at: http://www.unaids.org/en/resources/documents/2016/Global- AIDS-update -
2016. 31 May .  2016.
Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: 
significance, challenges, and opportunities [Author Manuscript]. Current 
HIV/AIDS reports 2011;8 (1):62-72.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 73 02 April 2019Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy  and their clinical 
relevance. Clin Pharmacokinet 1997;33 (5).
Lutz J, Shao Y, L ing J, Custodio J, Martin H, Quirk E, et al. Bictegravir/Emtricitabine/Tenofovir 
Alafenamide Phase 3 Exposure-Response Anal ysis of Safet y and Efficacy in the 
Treatment of HIV Infection [Poster 6]. 19th I nternational Workshop on Clinical 
Pharmacology  of Antiviral Therap y, May  22–24; 2018 May  22–24; Baltimore, 
Mary land. 
Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of 
mortal ity across Europe in patients infected with HIV
-1. EuroSIDA Study  Group. 
Lancet 1998;352 (9142):1725-30.
Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. Dolutegravir 
Pharmacokinetics in Pregnant and Postpartum Women L iving with HIV. AIDS
2018;32 (6):729 -37.
Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. Declining 
Morbidity  and Mortalit y Among Patients With Advanced Human 
Immunodeficiency  Virus I nfection. N Eng J Med 1998;338 (13):853-60.
Panel on Antiretrovir al Guidelines for Adults and Adolescents. Guidelines for the Use of 
Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of 
Health and Human Services. Available at 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. La st 
Updated : 27 March.  2018.
Panel on Treatment of Pregnant Women with HIV I nfection and Prevention of Perinatal 
Transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant 
Women with HI V Infection and Interventions to Reduce Perinatal H IV 
Transmission in the United States. Available at: 
http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf . Last Updated: 7 
December.  2018.
Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI . Morbidity  and Mortalit y 
Weekly  Report (M MWR). Revised Surveillance Case Definition for HIV 
Infection - United States 2014. Centers for Disease Control and Prevention,  2014.
Stek A, Best B, Luo W, Capparelli E, Burchett S, Hu C, et al. Effect of pregnancy  on 
emtricitabine pharmacokinetics. HIV M ed 2012;13 (4):226 -35.
Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term effectiveness 
of potent antiretroviral therapy in preventing AIDS and death: a prospective 
cohort study . Lancet 2005;366 (9483):378-84.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 74 02 April 2019Sterrantino G, S antoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self- reported adherence supports 
patient preference for the single tablet regimen (STR) in the current cART era. 
Patient preference and adherence 2012;6:427 -33.
Watts D, Stek A, Best B, Wang J, Capparelli E, Cressey  T, et al. Raltegravir Pharmacokinetics 
during Pregnancy  [Author Manuscript]. J Acquir Immune Defic S yndr. 2014;67 
(4):375-81.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 75 02 April 201911. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Maternal and Neonatal Study Procedures Tables
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential and 
Postpartum Contraceptive Requirements
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 77 02 April 2019Appendix 2. Maternal and Neonatal Study Procedures Tables
Maternal 
Study Procedures Table
Study Procedure Screening Day 1Visits before the deliveryDelivery 
VisitjPost-partum Visit
30-Day 
Follow -up Visit ESDD Week 4Weeks 8, 12, 16, 
20 & 24 
(dependent on 
time of 
enrollment)aWeek 6 Week 12
Written Informed 
ConsentX
Medical History X
Com plete Physical 
Examinationb X X X XbX X X
ECG X
Symptom -directed 
Physical Examinationc XcX
Vital Signs (including 
weight)X X X X X X X X
Height X
Laboratory 
Assessmentsd X X XdX X X X
Maternal alfa-
fetoprotein levelX
Urine Pregnancy TesteX X X X
eGFRfX X XeX X
HIV-1 RNA X X X X X X X X X
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 78 02 April 2019Study Procedure Screening Day 1Visits before the deliveryDelivery 
VisitjPost-partum Visit
30-Day 
Follow -up Visit ESDD Week 4Weeks 8, 12, 16, 
20 & 24 
(dependent on 
time of 
enrollment)aWeek 6 Week 12
Whole Blood Sample 
for HIV- 1 Genotypingg X
CD4+ cell count X X X
HBV and HCV Testing X
UltrasoundhX
Intensive PK Sample 
Collectioni, j X X X X
Sparse PK Sample 
Collectionk X
Plasma Storage Sample X X X X X X
PBMC Sample 
Collectionl X X X X
Drug and Alcohol 
ScreeningX X
Adverse Event and 
Concomitant 
Medication ReviewX X X X X X X X X
Date of Delivery X
Pregnancy outcome X
B/F/TAF Dispensation X X X X X
B/F/TAF 
AccountabilityX X X X X
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 79 02 April 2019a. After completion of the Week 4 visit, participants will be required to come back for a study visit every 4 weeks (Weeks 8, 12, 16, 20, 24 dependent on time of enrollment and 
time of delivery). Study visits may be completed within ± 2 days of protocol -specified visit date. 
b. A complete physical examination will be completed at Day 1, Week 4, Week 12 and Weeks 6 and 12 post-partum visits, and at the ESDD visit. 
c. A symptom directed physical examination will be completed at Weeks 8, 16, 20 and 24 visits and at the 30 -Day Follow -up Visit .
d. Clinical laboratory assessments include hematology, chemistry and urinalysis which will be completed at Screening, Day 1, Wee ks 12 and 24, Weeks 6 and 12 post-partum
visits, 30 -Day Follow -up Visit and ESDD Visit. 
e. Urine pregnancy testing will be completed at the ESDD if it is clinical appropriate and the subject is in the post -partum phase of the study.
f. eGFR will be calculated at Screening, Day 1, Weeks 12 and 24, and Weeks 6 and 12 post-partum visits.
g. Sample may be collected at Screening OR Day 1.
h. Ultrasou nd should be completed prior to the Day 1 visit. An ultrasound completed prior to the screening visit is acceptable.
i. Before delivery, Intensive PK sample collection will be completed after subject administers B/F/TAF for at -least 3 weeks. For participants enrolled during the second 
trimester, iPK sample collection will be completed at or between 20 to 28 weeks of gestation and at or between 30 to 38 weeks of gestation. For participants enrolled during 
the third trimester, iPK sample collection will be completed at or between 30 to 38 weeks of gestation.
j. After delivery, iPK sample collection will be completed at Week 6 and Week 12 post-partum visits.
k. Asingle maternal blood sample and a n umbilical cord sample after cord clamping will be collected at the time of delivery (Delivery Visit).
l. For participants enrolled at sites that can process PBMC samples, a trough PBMC sample will be collected 24 hours following the in -clinic dose administe red at the iPK 
visits.
m. The day of delivery will be considered as the Delivery Visit for study purposes.
Neonatal Study Procedures Table
Study Procedure Delivery Visit 4-8 Weeks of age
Com plete Physical Examination X X
Vital signs X X
Apgar scorenX
Anthropometric measuresoX X
HIV-1 RNA and Safety AssessmentspX X
Sparse PK Sample CollectionqX
n. Apgar score will be collected if it is recorded at the time of birth per standard of care
o. Head circumference, weight and length at birth and 4-8 weeks of age will be collected
p. HIV-1 RNA and safety assessments which includes CBC, LFTs (ALT, AST, total and direct bilirubin) may be completed using the spars e PK samples collected on the day of 
birth, if there is sufficient volume. If blood volume is insuffic ient, results from testing performed per standard of care will be obtained. HIV-1 RNA and safety assessments 
will also be completed at 4 -8 weeks of age if possible or results from testing performed per standard of care will be obtained. 
q. Sparse PK blood sa mples will be collected at the following time points , if possible : at or between 0 to < 2 hours, 2 to < 3 hours, 3 to 8 hours, 18 to 28 hours, 36 to 72 hours, 
and 5 to 7 days after birth. These time points may vary based on birth weight, additional instructions will be included in the Pharmacokinetic Sample Collection and 
Processing Instructions Manual.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 80 02 April 2019Appendix 3
. Management of Clinical and Laboratory Adverse Events
          
      
      
      
   
 
         
  
        
          
     
 
       
    
    
    
   
    
     
   
 
       
    
  
   
  
      
    
    
  
 
 
      
 
  
   
     
    
    
       
    
  
 
  
 
 
  
  
   
   
   
   
   
  
   
    
 
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 81 02 April 2019Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV positive ornegative )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count
Adult and Pediatric, 
≥ 7 Months# 1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric > 13Years 300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 82 02 April 2019HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 13Years 600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio of 
prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66 ULN 1.66 to 2.33 ULN 2.33 to 3.00 ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0% 
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric participant s.  Please follow the Gilead convention of 
grading any result within the lower limit of the normal range (LLN) and ULN a 0.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 83 02 April 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to 130mEq/L 121 to 125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to 130mmol/L 121 to 125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to 3.0mEq/L 2.0 to 2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to 3.0mmol/L 2.0 to 2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to 3.0mEq/L
2.5 to <3.0 mmolL2.0 to2.5mEq/L
2.0 to <2.5 mmolL2.0 mEq/L 
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to 55mg/d L
2.20 to 3.03 mmol/L30 to 40mg/d L
1.64 to 2.20 mmol/L30 mg/dL 51681 
1.64 mmol/L
Infant, 1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 84 02 April 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L6.1 to 7.0mg/dL
1.51 to 1.74 mmol/L6.1mg/d L
1.51 mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL 
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL
1.51 to < 1.74 mmolL< 6.1 mg/dL
< 1.51 mmol/L
Infant, 7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant, 7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to 2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to 0.74 mmol/L 0.49 to 0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to 0.58 mmol/L 0.28 to 0.43 mmol/L 0.28 mmol/L
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 85 02 April 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia 
Adult and Pediatric
≥ 1 year
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to 1.5 mg/dL
57 to 87 μmol/L0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 86 02 April 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Creatinine** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL 
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to 16.0 mEq/L 8.0 to 11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to 16.0 mmol/L 8.0 to 11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to 11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to 11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to 6.0 ULN 6.0 to 10.0 ULN 10.0 to 20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male participants >70 yrs. Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 87 02 April 2019ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 88 02 April 2019URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to 1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499 to799 mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes:
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratorie s, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (eg, the severity of an A E could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 89 02 April 2019CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND 
Non-urgent medical 
intervention indicatedSymptomatic, 
non-life-threatening AND 
Non-urgent medical 
intervention indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140– 159mmH g systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 90 02 April 2019CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated 
(eg,anticoagulation, lysis 
filter, invasive procedure) Deep vein thrombosis AND 
Intervention indicated 
(eg,anticoagulation, lysis 
filter, invasive procedure) Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consci ousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 91 02 April 2019RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% 
to49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 92 02 April 2019SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerCom plete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving 
twoor more distinct 
mucosal sites OR Toxic 
epidermal necrolysis 
(TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 93 02 April 2019GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 94 02 April 2019GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 
24-48hoursPersistent nausea resulting in 
minimal oral intake for 
48hours OR Aggressive 
rehydration indicated 
(eg,IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis 
(functional -symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening consequences 
(eg, hypotensive shock)
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 95 02 April 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in 
Personality -Behavior or in 
Mood (eg, agitation, 
anxiety, depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual so cial & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic s elf-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic 
self-care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
Central nervous system 
Ischemia (acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 96 02 April 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or
other neurologic function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care f unctions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 97 02 April 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive 
(eg,status epilepticus), or 
difficult to control 
(eg,refractory epilepsy)
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of 
pre-existing seizures 
(non-repetitive) without 
change in seizure character 
OR infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality 
(eg,severity or focality) Seizures of any kind that are 
prolong ed, repetitive 
(eg,status epilepticus), or 
difficult to control 
(eg,refractory epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
5-20minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or without second ary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic 
self-care functions
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 98 02 April 2019MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic 
self-care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activi tiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic 
self-care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic 
self-care functions
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 99 02 April 2019SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR 
Life-threatening 
bronchospasm OR laryngeal 
edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6 C
99.8F to 101.5 F38.7C to 39.3 C
101.6 F to 102.8 F39.4C to 40.5 C
102.9 F to 104.9 F40.5C 
104.9 F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated 
[eg,tube feeding or total 
parenteral nutrition]
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 100 02 April 2019INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basic self-care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 9 9cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment (eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 101 02 April 2019ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew  onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities , 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 102 02 April 2019GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHem orrhage with 
life-threatening hypotension 
OR Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing 
life-threatening 
consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic an tiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 103 02 April 2019Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV 
(CDC Guidelines)
1) Candidiasis of bronchi, trachea, or lungs
2)Candidiasis of esophagus
3)Cervical cancer, invasive
4)Coccidioidomy cosis, disseminated or extrapulmonary
5)Cryptococcosis, extrapulmonary
6)Cryptosporidiosis, chronic intestinal ( 1 month duration)
7)Cytomegalovirus disease (other than liver, spleen or nodes)
8)Cytomegalovirus retinitis (with loss of vision)
9)Encephalopath y, HIV-
related
10) Herpes simplex: chronic ulcer(s) ( 1 month duration); or bronchitis, pneumonitis or 
esophagitis
11)Histoplasmosis, disseminated or extrapulmonary
12)Isosporiasis, chronic intestinal ( 1 month duration)
13)Kaposi’s sarcoma
14)Lym phoma, Burkitt’s (or equivalent term)
15)Lym phoma, immunoblastic (or equivalent term)
16)Lym phoma, primary , of brain
17)Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary
18)Mycobacterium tuberculosis , of any  site, pulmonary , disseminated or extrapulmonary
19)Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
20)Pneumocy stis jirovecii (previously  known as “ Pneumocystis carinii ) pneumonia
21)Pneumonia, recurrent
22) Progressive multifocal leukoencephalopathy
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 104 02 April 201923)Salmonella septicemia, recurrent
24)Toxoplasmosis of brain
25)Wasting sy ndrome attributed to HIV infection
26)CDC Stage -
3-Defining Opportunistic I llnesses in HIV Infection - 2014 {Selik 2014 }
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 105 02 April 2019Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing 
Potential and Postpartum Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically
 documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previou sly occurring menses for > 12 months without an alternative cause.  In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
2)Post-partum Contraception Requirements for Female Parti cipants
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Data from clinical pharmacokinetic interaction studies of B/F/TAF have demonstrated that there 
is no reduction in the clinical efficacy  of hormonal contraception. Non -clinical toxicity  studies of 
B/F/TAF have demonstrated no adverse effect on fertility  or embry o-fetal development. 
However, there are currently  no other clinical studies of B/F/TAF in pregnant women.  Please 
refer to the latest version of the investigator’s brochure for additio nal information.
b.Post-partum Contraception Requirements for Female Participants of Childbearing 
Potential
The inclusion of female Participants of childbearing potential requires using at least an 
acceptable effective contraceptive measure during the postpa rtum period until the end of study . 
The appropriate contraceptive measure and timing of initiation for women who are postpartum 
should be discussed with the healthcare provider managing the patient in the postpartum period. 
In the event of a delay ed menstr ual period after the resumption of menses in the postpartum 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy .  This is even true for women of childbearing potential with infrequent or irregular 
periods .  They  must also agree to one of the following from postpartum until 7 day s after the last 
dose of study  drug.
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line wit h the subject’s preferred and usual lifesty le.
Or
B/F/TAF
Protocol GS -US-380-5310 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 106 02 April 2019Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of <1% per y ear
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and had 
confirmation of surgical suc cess 3 months after procedure)
Barrier methods (one female barrier and one male barrier must be used in combination)
Female barriers: Diaphragm with spermicide or Cervical cap with spermicide
Male barriers: Male condom (with or without spermicide)
Hormonal methods
Oral contraceptives (either combined or progesterone only )
Injectable progesterone
Implants of levonorgestrel
Transdermal contraceptive patch
Contraceptive vaginal ring
Participants must also refrain from egg donation and in vitro fertilization during treatment and 
until at least 7 days after the last dose of study  drug .
3)Unacceptable Birth Control Methods During the Post -partum Period
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
4)Procedures tobe Followed in the Event of Pregnancy During the Post -partum Period
Participants will be instructed to notify  the investigator if they  become pregnant during the 
post-partum period of the study , or if they  become pregnant within 7days of last study  drug 
dose. Participants who become pregnant or who suspect that they  are pregnant during the 
post-partum period m ust report the information to the investigator and discontinue study  drug 
immediately . Instructions for reporting pregnancy  and pregnancy  outcome s that occur during the 
post-partum period of the study are outlined in Section 7.7.2.1.